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INTRODUCTION 
Liquid chromatography (LC) is a well-known and much-employed technique by 
analytical chemists which has undergone significant improvements over the last 
century. A substantial advancement in the field was the coupling of an LC 
instrument to mass spectrometry (MS) detector. While this expanded the limits 
of analytes that can be detected and quantified, it also put a considerable restric-
tion on how the analyte is delivered to the MS – both in terms of the LC mobile 
phase’s volatility, as well as the prepared sample cleanliness.  
In order to ensure an easier and often also a better detection of analytes in 
the MS samples need be separated from any possible lingering matrix and also 
from each other (in multi-analyte assays). The separation is done via analytical 
columns, which, due to the chemical properties of silica, historically have been 
and still are used in combination with acidic eluents. However, these conditions 
are not suited for pharmaceutical analysis (especially in the bioanalytical field), 
since the vast majority of analytes have basic properties, which results in them 
being insufficiently retained and poorly separated on a regular reversed-phase 
chromatography column. 
A potential option to change elution patterns without changing the column or 
detector is presented by novel fluoroalcoholic eluent additives – weakly acidic 
compounds with weak ion-pairing capabilities and with a positive influence on 
analyte ionisation in the MS source. Two additives: 1,1,1,3,3,3-hexafluoro-2-
propanol (HFIP) and 1,1,1,3,3,3-hexafluoro-2-methyl-2-propanol (HFTB) are 
already used in the analysis of oligonucleotides. Other fluorinated alcohols – 
perfluoropinacol (PP) and nonafluoro-tert-butyl alcohol (NFTB) are much less 
known, but they are no less interesting. Additionally, ammonium fluoride 
(NH4F), 2,2,2-trifluoroethanol (TFE) and dimethyl sulfoxide (DMSO) have 
been reported to have a positive influence on either the analyte sample clean-up, 
or ionisation, thus presenting potential for exploration. 
It is of interest to research and expand the knowledge about the highlighted 
compounds as LC-MS eluent additives. Furthermore, to study the influence on 
analyte retention not only on the C18 stationary phase, but also in the biphenyl 
and pentafluorphenyl (PFP) columns and to investigate the impact on analyte 
ionisation when novel additives are used in bioanalytical applications at more 
favourable mobile phase conditions – namely using a high pH. 
As the research focuses on pharmaceutical analytes, two practical applica-
tions – method development and validations using a fluorinated eluent additive 
as a key ingredient for success, have been developed and successfully imple-
mented in the analysis of real patient samples. Additionally, discussion about 
pharmacokinetically important data obtained from the bioanalytical methods 
that fall below the limits of quantification has been presented. The importance 
and perspectives for this data treatment will be outlined. 
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1. LITERATURE OVERVIEW 
1.1. Liquid chromatography and instrumentation 
The history of liquid chromatography (LC) begun more than a century ago as 
“classical column chromatography” when the separation of components from 
the mixtures was achieved in a glass tube filled with solid particles as the statio-
nary phase. Initially, coloured samples (plant pigments) were analysed, as thus 
the separation could be monitored visually. While the technique has matured 
through time, the main principle has remained the same – the separation of a 
mixture, on the basis of solvent and stationary material, in both cases either 
polar or nonpolar, with continuous monitoring with a detector at the end. The 
detector signal is then plotted against time and called a “chromatogram”. Mo-
dern LC instruments do not rely on gravity anymore, but use a high-pressure 
pump, to enable a faster and more efficient separation. Due to that, it is called 
high-performance liquid chromatography (HPLC). [1] 
In recent years, an even more powerful type of LC has become common, 
called either ultra-performance liquid chromatography (UPLC® – trademarked 
by Waters Corporation) or ultra-high-pressure liquid chromatography (UHPLC). 
The main difference between HPLC and UHPLC is that the latter uses pressures 
higher than UPLC®; in addition, it incorporates columns, which are packed 
with sub-2 µm particles and instruments capable of withstanding pressures of 
more than 1,000 bars (100 MPa). This shortened the analysis time and an 
optimised resolution, faster results and a higher sensitivity. The generic term 
UHPLC focuses only on the high-pressure aspect. [2] 
The LC system (Figure 1) in general can be coupled with a vast array of 
detectors, depending on the analytes in question. The most basic ones are ultra-
violet/visible light (UV/Vis) or diode-array detectors (DAD)/photodiode array 
detectors (PDA) where detection is based on light absorption. While UV/Vis 
detectors have relatively high sensitivity, they are easy to operate, reliable and 
cheap, they are not very selective. Other available options include fluorescence, 
conductivity, refractive index, light-scattering, corona-charged aerosol detec-
tors. [1] 
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Figure 1. The schematic of an HPLC system, consisting of 1 – solvent reservoirs,  
2 – a high-pressure pump, 3 – a sample injection system, 4 – an analytical column, 5 – a 
detector and 6 – a data acquisition a platform.    
 
 
The most versatile HPLC addition is a mass spectrometric (MS) detector. This 
detection type has become a reliable tool in bioanalytical methods, especially 
when analysing pharmaceuticals in biological matrices (most commonly human 
blood, plasma or urine). The MS extracts ions according to their mass-to-charge 
ratio (m/z), quite often protonated molecule [M+H]+. More sophisticated  
tandem-MS or hybrid-MS systems first isolate a precursor ion and fragment it 
into several product ions, which again are isolated or collectively scanned for. 
The latter provides the much-needed selectivity, as differently structured 
compounds can form ions of the same m/z. Other detectors include Fourier-
transform infrared spectroscopy (FTIR) and nuclear magnetic resonance (NMR). 
[1], [3] 
 
 
1.2. The stationary phase (column) and  
its role in analyte separation 
The modern LC-column is still a tube, packed with particles carrying the statio-
nary phase. Most commonly they are silica particles, but other types (e.g. zirco-
nia or alumina) are also available. Silica particles have “functional groups” 
attached via siloxane bonds, which together can be considered the column’s 
stationary phase (Figure 2). The functional groups determine what kind of 
analytes can be selectively retained. Columns with short carbon chains of C3, 
C4, or C5 functional groups are primarily used for separating proteins, while 
columns with diol groups are used in size exclusion chromatography (SEC). 
Traditionally, the columns are categorised by their functional group (C18, 
biphenyl etc.), particle size, column internal diameter and length. [1] 
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Figure 2. Different types of reversed phase columns organised according to functional 
groups (the figure does not show connecting [-Si(CH3)2-] silane group). TMS – 
trimethylsilyl group, ODS – octadecylsilyl group. 
  
     C1
  (TMS)
C3 C5       C8 C18
(ODS)
          C30   
Alkysilica columns
Phenyl columns Cyano column “Other” columns
Column type X Sub-type
Embedded-polar-group R-NH-(C=O)-O- Carbamate 
R-NH-(C=O)- NH Urea
R-(C=O)- NH Amide
Fluoro columns:
Pentafluorophenyl (PFP)
-CF2- CF2- CF3 Fluoroalkyl
17 
1.2.1. Retention time and the retention factor 
Retention time (tR) is the time between the sample injection, and the apex of the 
peak of an analyte. The shortest retention time is found for compounds un-
retained on the column under used the chromatographic conditions and is called 
hold-up time, void volume or dead time t0. The retention factor k (sometimes 
also called the capacity factor) is defined as the time the sample component 
resides on the stationary phase, relative to the time it is located in the mobile 
phase (equation 1). [1], [4] 
The retention factor is calculated with the following formula (1). 
 
𝑘 =  ௧ೃି௧బ௧బ  (1) 
 
where k – retention factor, tR – retention time, t0 – dead time 
A very precise value for k is usually not required for developing a method or 
during routine analysis, but it is preferable if the retention factor value lies 
between the values 1 and 10. If, for all peaks k ≤ 10, it means there is an 
efficient use of resources – a shorter analysis run time per one sample and more 
samples analysed per day. Additionally, the obtained peaks are narrower and 
higher, which leads to improved detection. However, if k is below 1, analytes 
elute early in the chromatographic run, may have poor resolution and can be 
distorted by interferences from the matrix. This parameter can help with the 
evaluation and comparison of different methods and the analyte retention in the 
column. [1] 
 
 
1.2.2. Interactions in the reversed-phase column  
Taking into account all stationary phases, 80-90% assays use reversed-phase 
(RP) chromatography columns [5]. The basis of analyte retention on RP 
depends on the interactions between the analyte, the non-polar stationary phase 
(column) and the polar mobile phase (eluent). The column types used in this 
dissertation include the C18, biphenyl and pentafluorophenyl (PFP) stationary 
phases and are all representatives of RP chromatography. Altogether these inter-
actions can be divided into eight types (Figure 3) – (1) hydrophobic interaction, 
(2) steric interaction (exclusion of large analyte molecules from the stationary 
phase), (3) and (4) are hydrogen bonding – between a donor and acceptor within 
the stationary phase – where one is basic and the other is acidic, either the 
analyte or the stationary phase, (5) ionic interaction, (6) dipole-dipole inter-
action and (7) π-π interactions between aromatic analytes and nitrile or (8) π-π 
interactions between aromatic analytes and a phenyl group in the stationary 
phase. [1] 
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Figure 3. Analyte interactions with the column’s stationary phase in RP. 
 
 
Interactions 1–5 are important in any column; dipole-dipole interactions are 
relevant only in the case of the cyano-column, π-π interactions are present only 
for phenyl and cyano-stationary phases. Furthermore, acetonitrile (ACN) as 
mobile phase component inhibits dipole and π-π interactions. [1], [6] Hydro-
phobic interactions are deemed to be the most powerful in the C18 column [7], 
but other interactions can influence the selectivity of the RP column as well [1]. 
However, unlike the C18, biphenyl stationary phase has a very high hydrogen-
bonding capacity [7]. Also PFP stationary phases, when compared to alkyl 
phases, provide alternative retention and selectivity. This is due to the additional 
interactions (π-π, dipole, hydrogen bonding, and ionic interactions) which are 
not as dominant in the common alkyl stationary phases. For positively charged 
analytes, the dominating interaction is often ion-exchange. However, the pre-
valence of this interaction is very dependent on the column manufacturing pro-
cess, as it is speculated that the main source of this interaction comes from 
ionised surface silanol groups, not the PFP ring system itself. In any case, due to 
the prevalence of ion-exchange interaction in the PFP column, it is especially 
important to monitor pH conditions. [8], [9] 
 
  
1. Hydrophobic 
interaction
2. Steric
exclusion
3. Hydrogen 
bonding (basic 
solute)
4. Hydrogen 
bonding (acidic 
solute)
5. Ionic 
interaction
6. Dipole-dipole 
interaction
7. π-π interaction 
(phenyl column)
8. π-π interaction 
(cyano column)
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1.2.3. Reversed phase column and pH 
The most popular packing material of the RP phase columns is silica. Silica 
does not swell or shrink when in contact with organic solvents. Furthermore, it 
possesses high mechanical strength, which is especially needed for the high-
pressure conditions in HPLC. By now, both the manufacturing and mechanics 
of columns are well explored and reproducible [10]. Thus, silica appears to be 
the ideal substrate for mass production. Unfortunately, it also has a downside – 
namely, liability to deterioration [10], [11]. Columns with short-chain ligands 
like C3 are the most unstable at a low (below 2) pH. However, the mobile phase 
with pH >8 can lead to the dissolution of silica packings. If the bonded phase is 
lost, it means that the column performance or so-called “column lifetime” de-
creases. The manufacturer provided recommendations should always be 
followed, especially for temperature and the mobile phase pH. [1] The dete-
rioration rate depends on what type of functional groups are bonded to the 
silica, the eluent’s composition, and a myriad of other experimental parameters. 
However, the process of the column’s stationary phase breakdown due to the 
pH can be divided into two mechanisms [11]: silica dissolves even in the  
pH 2–7 and reaches saturation of 100 ppm [11], but if the pH rises above 7, the 
process speeds up considerably [12]. The backbone of silica breaks down, 
which greatly reduces the column’s plate numbers (the parameter describing 
column’s efficiency) and eventually results in the column clogging. In the case 
of an acidic pH, it is not silica but the covalent siloxane bond responsible for 
binding the functional groups that undergoes hydrolysis [12]. A high tempe-
rature significantly accelerates the degradation processes for both low and high 
pH mobile phases [1]. 
While the rapid deterioration in a high pH environment is unavoidable, the 
rate at which this happens varies greatly depending on the manufacturer. Resis-
tance to a high pH depends primarily on the silica chosen as the substrate at the 
very beginning of column production, as well as the possible contamination 
with metals. [10], [11] There are multiple things employed nowadays for 
expanding the resistance to very high or low pH environments. One of them is 
obtained through a hybrid organic-inorganic process (silica-silane or zirconia 
based particles are resistant to a high pH) and results it in endcapping the 
unbonded silanol groups [1], [13]. If the bonded alkyl chains are longer, the 
resistance to a high pH increases as well, as long as the temperature remains 
below 40 ⁰C [1], [10].  
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1.3. The mobile phase in LC 
In RP-LC organic solvents are most common as mobile phases, using methanol 
(MeOH) and ACN in combination with deionised water. To further improve the 
analysis efficiency, mobile phase additives are commonly used as easily ad-
justable parameter. By supplying an extra additive, commonly a buffering 
agent, it is possible to change various properties of the mobile phase such as the 
pH, ionic strength or ion-pairing capabilities. The addition of an eluent additive 
can also influence the retention of the analyte in the column and the ionisation 
in the MS. [14] While coupling an MS facilitates a more precise detection as 
well as increases the variety of analytes possible to detect, it also introduces 
limitations. The greatest limitation of mass spectrometers is the requirement of 
the mobile phase to be volatile. This excludes many commonly used LC-
UV/Vis eluent additives. For LC-MS systems, the most commonly used eluent 
additives (which are also relatively inexpensive) are thus acetic and formic 
acids (FA), their ammonium salts, as well as ammonium bicarbonate. The 
buffering range of ammonium bicarbonate is 6.8 ≤ pH ≤ 11.3. The buffering 
range of ammonium formate is 2.8 ≤ pH ≤ 4.8 [15], while for ammonium 
acetate two buffer ranges can be achieved between 3.8 ≤ pH ≤ 5.8 and  
8.2 ≤ pH ≤ 10.2. [14]–[16] 
 
 
1.4. The importance of acid-base equilibrium 
In the past, the separation of ionised analytes (containing basic, acidic or both of 
the functional groups) was rather complex, due to the lack of appropriate 
columns available and a limited understanding on how best to carry out 
analyses with these analytes. While these limitations have mostly been over-
come, the ionised analytes still present a complex challenge. [1], [14] The 
charge (protonation) state and thus also the interactions of the analyte with other 
analytes, eluent additives or the stationary phase are determined by the pH of 
the environment. It is important that the mobile phase’s pH should be both 
controlled and stable – which is achieved with the use of buffering agents. [14] 
When an analyte (acid AH or base B) undergoes ionisation in the mobile 
phase due to the pH, it becomes more polar – either as a deprotonated acid A- or 
a protonated base BH+. The retention factor can decrease more than 10 times 
due to this effect (Figure 4). [1] 
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Figure 4. The ionisation of acidic (AH) and basic (B) analytes as a function of the 
mobile phase’s pH.  
 
 
To further complicate matters, the addition of an organic solvent, either con-
stantly or gradually, to the aqueous buffer (the pH of the water phase can be 
expressed as pH୵୵  [17]) alters the pH of the mixture and therefore also the rate 
of the protonation/deprotonation of bases and acids. Hence, as critical as the pH 
of the aqueous component, also the pH of the whole eluent is important. This 
pH can be expressed either as the pH (pHabs) [18] or the solvent-water pH 
( pH)୵ୱ  [17]. The pH୵ୱ  value is obtained, when the electrode is calibrated in 
aqueous solutions, but the pH is subsequently measured in the organic-water 
mixture. This approach does not account for the liquid junction potential (LJP) 
at the pH-electrode in the eluent. It functions unlike pHabs, which expresses the 
acidity of the mobile phase in terms of its proton’s thermodynamic activity. 
Thus, the measured pHabs values in different solvents, mixtures, etc. become 
comparable. [17] 
The change in the eluent’s pH due to the addition of an organic component, 
as well as the variation in the analyte’s pKa values, can be modelled. Based on 
both of these parameters, it is also possible to estimate the degree of the 
ionisation of the analytes and possibly predict the analyte elution patterns. The 
extent of changes depends on the organic component and its fraction in the 
eluent, the concentration of the buffer component and the aqueous pH, as well 
as the nature of the buffering system. For both MeOH and ACN, the pH 
alteration has a linear relationship with the volume fraction of the organic phase 
and the aqueous pH. The pKa values of neutral or anionic acids, e.g. phenols, 
aliphatic and aromatic carboxylic acids, increase with the addition of an organic 
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solvent. In contrast, the pKa values of pyridines and amines, as cationic acids, 
decrease. [17] 
Another important parameter that is influenced is the buffering capacity. It 
describes how much of a strong base or acid has to be added to a system to 
achieve one pH unit change in the solution. The highest buffer capacity is 
reached if the acid and the conjugated base species are in equal concentration – 
meaning that the pH of the solution is equal to the pKa. The addition of the 
organic solvent to the mixture shifts the maximums of buffer capacities, 
however the scope of this influence is unique to every buffer. For anionic or 
neutral buffers (citric, acetic and phosphoric systems) this maximum is moved 
to a higher pH୵ୱ , but for cationic acid buffers (ammonia) it is shifted to lower 
pH୵ୱ . Furthermore, the increase in the volume fraction of the MeOH in the 
eluent decreases the pH୵୵  value for ammonia buffers. [17] 
 
 
1.5. Novel eluent additives 
The requirement of volatility for an eluent additive vastly decreased the number 
of usable buffers applicable with the LC-MS systems. Furthermore, analytes 
which can be ionised in the eluent demand careful consideration of their mobile 
phases. Thus, the need for novel eluent additives, compatible with MS systems 
has never been greater. One prospective group of novel eluent additives is 
fluoroalcohols (Table 1), which can also alter the selectivity of both mobile and 
stationary phases in LC. 
The proposed way of action for fluoroalcohols is as follows – the fluorinated 
compounds cover the stationary phase, in the case of C18, and create a hydro-
philic layer exposing their polar hydroxy (-OH) group to the mobile phase, 
which becomes a possible hydrogen bond donor. If the pH of the mobile phase 
is higher than the pKa, the OH group becomes deprotonated and the anions of 
fluoroalcohols can create ion pairs with the protonated basic species both in the 
eluent and on the stationary phase. This results in an increase in retention. 
Acidic ionic analytes, however, are hindered due to a competition with fluoro-
alcohols for the surface on the stationary phase, as well as the repulsion by the 
deprotonated (-OH) groups. Thus, the retention of acidic analytes decreases. 
[25] 
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Table 1. Promising novel eluent additives and their structures. 
 
Name Abb-reviation 
CAS 
number Structure pKa 
pKa 
reference 
1,1,1,3,3,3-
hexafluoro-2-
propanol 
 
HFIP 920-66-1 
F3C CF3
OH
9.3 [19] 
1,1,1,3,3,3-
hexafluoro-2-
methyl- 2-
propanol 
HFTB 1515-14-6 CF3F3C
OHCH3 9.6 [20] 
2,2,2-
trifluoroethanol 
 
TFE 75-89-8 F3C
CH2
OH 12.5 [21] 
perfluoropinacol 
 PP 918-21-8 
CF3
CF3OH
OH
F3C CF3 pKa1 = 5.95 pKa2 = 10.43 [22] 
nonafluoro-tert-
butyl alcohol NFTB 2378-02-1 F3C
OH
CF3
CF3 5.33 [22] 
difluoro acetic 
acid DFA 381-73-7 OH
O
F
F
0.013 [23] 
ammonium 
fluoride NH4F 12125-01-8 N
+
H
H
H H
F-
- - 
dimethyl sulfoxide 
 DMSO 67-68-5 
CH3
S
CH3
O
35 [24] 
 
 
1.5.1. 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP) 
Fluoroalcohols such as 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP, Table 1) are 
well known as weakly acidic eluent additives in the analysis of oligonucleo-
tides, mainly due their impressive signal enhancement properties [26]. HFIP 
also behaves as an ion-pairing reagent and has demonstrated how it can alter 
selectivity [25] and successfully improved results in the analysis of antibiotics 
(ofloxacin, ciprofloxacin, sulfadimethoxine, norfloxacin and sulfamethoxazole) 
in lettuce samples. [27] Just like any other alcohol, HFIP is an excellent solvent. 
However, it alters the function of cell membrane proteins as well as changes the 
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properties of the lipid bilayers far stronger than its un-fluorinated alcohol 
counterpart. While unsaturated lipids can bind to HFIP without compromising 
the membrane’s integrity, saturated lipids form particles with HFIP  [28], [29]. 
The unique properties of HFIP, in forming strong hydrogen bonds (there can be 
many HFIP molecules per one head group of a lipid) and HFIP having a high 
octanol/water partition coefficient, can be named as reasons for this [28]. 
 
 
1.5.2. 1,1,1,3,3,3-Hexafluoro-2-methyl-2-propanol (HFTB) 
Similarly to HFIP, also 1,1,1,3,3,3-hexafluoro-2-methyl- 2-propanol (HFTB, 
Table 1) is weakly acidic and has ion-pairing capabilities [25]. HFTB has also 
been used in the analysis for oligonucleotides, and depending on the oligo-
nucleotide type, has produced an even higher signal enhancement than HFIP 
[26], [30]. 
 
1.5.3. Perfluoropinacol (PP) 
Perfluoropinacol (PP) or 1,1,1,4,4,4‐hexafluoro‐2,3‐bis(trifluoromethyl)butane‐
2,3‐diol (Table 1) is a promising candidate as a fluorinated eluent additive pos-
sessing not one, but two OH groups. However, to the best of the author’s know-
ledge, no previous research has been conducted with PP as an eluent additive. 
 
 
1.5.4. Nonafluoro-tert-butyl alcohol (NFTB) 
Scarce information can be found about nonafluoro-tert-butyl alcohol (NFTB, 
Table 1) as a possible eluent additive, except for one example in oligonucleotide 
research in which signal suppression was observed [26]. NFTB also has lipid 
bilayer destabilising properties, even greater than those of HFIP [29]. 
 
 
1.5.5. 2,2,2-Trifluoroethanol (TFE) 
The use of the eluent additive 2,2,2-trifluoroethanol (TFE, Table 1) has been 
demonstrated as suitable for cleaning an LC system as well as columns from 
proteins and peptides without suppressing the MS signal [31]. Changes in an 
analyte’s signal strength were also observed in oligonucleotide research. Rather 
than a straightforward enhancement or suppression, a higher charge state of the 
oligonucleotide is achievable with TFE, in contrast to HFIP, but it lacked good 
chromatographic properties [26]. Similarly to HFIP, also TFE has been proven 
to have lipid bilayer disruptive properties, albeit less strong than those of HFIP 
and NFTB [29]. 
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1.5.6. Dimethyl sulfoxide (DMSO) 
Dimethyl sulfoxide (DMSO, Table 1) is not yet a common eluent additive. 
However, it became a potential candidate to research when its positive influence 
on ionisation in the field of proteomics was discovered [32]–[34]. This was ob-
served, when DMSO was used in low (5%) concentrations in the MS detection 
of peptides derived from trypsin, elastase or pepsin digestion [32]. 
 
 
1.5.7. Ammonium fluoride (NH4F) 
Ammonium fluoride (NH4F, Table 1) has previously been successfully applied 
within our research group, and it showed a significant enhancement of the 
ionisation of steroid-like molecules in the positive ion detection mode [35]. 
Thus far, however, the research has focused on the effects of ammonium 
fluoride in the negative detection mode. A study was conducted which aimed to 
quantify brevetoxins – a polycyclic, lipid-soluble family of toxins originating 
from algae [36]. In favourable conditions, the algae rapidly reproduce and 
release brevetoxins, inducing toxicity in marine mammals, fish, and humans 
who consume contaminated shellfish. Since these analytes are lacking acidic 
groups, they produce only a very small signal in the negative mode electrospray 
mass spectrometry (ESI-MS). Multiple anions were researched, and it was dis-
covered that, although brevetoxins formed ion adducts (for example [M+Cl]−, 
[M+Br]−, [M+OAc]−, [M+HCOO]−, [M+NO3]− ), it was NH4F and bicarbonate 
which provided the necessary further fragmentation for identifying the toxins. 
Furthermore, NH4F yielded more fragments and a far higher signal than bi-
carbonate. [36]  
To avoid the usually employed derivatisation to increase the sensitivity for 
the detection of estrogen (both estrone E1 and oestradiol E2), the influx of 
fluoride ions was tested. They provided the needed improvement. [37] Simi-
larly, for the two steroid hormones Δ4- and Δ7-dafachronic acid (isomers), 
NH4F was successfully employed [38]. The effect of enhancement still appears 
to be analyte specific – as signal suppression is also possible [39]. Most pro-
bably, the mechanisms of ionisation enhancement in the negative mode origi-
nates from the strong basicity fluoride ions possess in the gas phase. This allows 
them to attract protons from neutral molecules. They produce HF, meanwhile 
forming [M+FHF]- clusters and [M+F]- ions. Meanwhile enhancements have 
also been observed in the positive ion detection mode for organic acids, using 
normal phase chromatography. [36], [40] 
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1.5.8. Difluoroacetic acid (DFA) 
Difluoroacetic acid (DFA) is the only carboxylic acid from all researched eluent 
additives (Table 1). A promising application note has shown that DFA has both 
ion-pairing and signal enhancement properties, it additionally provides better 
peak shapes for peptide analysis when compared to other commonly used eluent 
additives such as formic acid (FA) and trifluoroacetic acid (TFA). [41] 
 
 
1.6. Challenges in the bioanalytical applications for  
small molecules  
Basic conditions for RP separation are best suited in the case of pharmaceutical 
analyte analyses since over 70% of the analytes have basic properties, but only 
approximately 20% are acids. Basic analytes are protonated when the eluent’s 
pH is lower than the analyte’s pKa value and thus have poor retention in RP 
conditions [42]. However, because the high pH damages the silica-based analy-
tical columns, acidic mobile phases have been preferred, which means the 
conditions for the analysis for basic analytes are less than satisfactory [1]. 
Meanwhile, there is a need for pharmacokinetic (PK) and pharmacodynamic 
(PD) studies of pharmaceutical analytes – especially in the complicated studies 
focusing on paediatric patients [43], [44]. Low concentrations of analytes 
needed to be quantified, and very limited amounts of allowed sampling volumes 
in term and preterm neonates, which result in a very small final sample volume 
are ever-present issues increasing the complexity of study management [45]–
[47]. While the need for more sensitive and efficient methods increases, the data 
obtained still require to be reported with the same trustworthiness and strict 
validation as in other bioanalytical methods [48], [49].  
Additionally, regarding the very low concentrations of an analyte and tight 
guidelines regulating what results can be released, a significant amount of the 
obtained data for PK/PD studies can and do fall below the limit of quantifica-
tion (BLQ) and cannot be released – simply because of the BLQ data precision 
and the data missing accuracy. The reasons, why analyte concentrations fall 
BLQ are manifold, including that the drug concentration has decreased too 
much – especially for late time points in the PK studies [50]–[54], and when the 
parent drug degrades very rapidly [55]. Too low concentrations can also be a 
result of individual variability (the influence of how the drug is absorbed, 
excreted or degrades) [56]–[59] and the fact that the administered dose might 
simply have been too small [60]–[64]. The lack of data BLQ has forced scientist 
to use statistics to create a smaller bias and more accurate parameter estimates 
[65], [66]. 
Two types of medication requiring PK/PD studies in paediatric patients can 
be taken as examples – sedative and cardiovascular drugs. An area, where seda-
tion is commonly needed, is the intensive care units (ICU).  Due to the vulnerable 
patient population, only limited sample volumes are available. Additionally, the 
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probability to have samples with a very low drug concentrations is large – 
possibly even below limits of quantification for methods not sensitive enough. 
[67] Moreover, there is increasing awareness of difficulties presented by over-
sedation and the simultaneous need to ensure sufficient sedation, while also 
matching individual needs [68]. Reduction in the usage of benzodiazepines by 
switching to alpha-2 adrenergic receptor agonists (e.g. clonidine) as an attempt 
to avoid the side effects (tolerance and withdrawal) are hindered due to a lack of 
data, research, and the understudied sedative requirements [68], [69]. As for 
cardiovascular drugs, the amount of paediatric patients (especially infants) who 
need milrinone has increased by four times since 2005, and there has been a 
steady increase in the administration of milrinone also in ICUs. The reasons for 
the administration of milrinone included persistent pulmonary hypertension, 
low cardiac output syndromes. Additional medication administered alongside 
milrinone is fentanyl, midazolam, furosemide and dobutamine. [70] 
As mentioned previously, benzodiazepines are common in ICUs, the most 
popular being midazolam, lorazepam, and diazepam [71]. Midazolam has hyp-
notic, sedative and anxiety preventing properties [72] and, as a gamma-amino-
butyric acid (GABA) agonist, it is metabolised in the liver to active metabolites 
[71]. In the case of midazolam, its primary active metabolite is 1’-hydroxymida-
zolam (MiOH) [73].  
Commonly used opioids in ICUs include morphine, hydromorphone, fenta-
nyl, and remifentanil [71]. Morphine is highly addictive, and a tolerance to it 
develops equally fast [74]. More than a half (56%) of a morphine dose is 
metabolised to the active metabolites morphine-3-glucuronide (M3G) and 10% 
is converted into morphine-6-glucuronide (M6G). Other metabolites include 
hydromorphone and the non-active metabolite normorphine. [75] M3G and 
M6G are hydrophilic, but the latter crosses the blood-brain barrier more readily 
and has been deemed to have more potency as an analgesic than either M3G or 
morphine [76]. M3G and M6G especially present a challenge for MS detection, 
because both have the same molecular mass and fragmentation patterns – and 
produce a morphine ion [M+H]- during the fragmentation [77], [78]. Multiple 
bioanalytical methods have been developed with varying success in separation 
of the M3G and M6G as distinct peaks. Largely separation has been achieved 
[77], [78], however, in some assays – [74], [79], [80] it has been more proble-
matic, with M3G and M6G eluting early during the chromatographic run and/or 
with morphine, M3G and M6G peaks close to each other. 
The administration of clonidine lowers the blood pressure and decreases the 
heart rate because it stimulates the alpha (2)-adrenoceptors in the central ner-
vous system (CNS) [81]. Due to this, clonidine is not only used as an antihyper-
tensive drug, but also for analgesia and sedation [82]. However, in ICUs the 
main use of clonidine is treating withdrawal symptoms as well as the addition of 
clonidine to the sedation regimen allowed to lower the opioid dosage [71]. 
Milrinone affects the muscle contractions in the muscle tissue of the heart as 
well as the vascular smooth muscle by inhibiting the enzyme phosphodiesterase 
3. Therefore, the inhibitors of the enzyme have a therapeutic influence also on 
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the lungs, not only the heart. The elimination half-time for milrinone is 2.3 
hours, with two main excretion products (via urine) – milrinone (83%) and its 
glucuronide metabolite (12%) [83].  
Dobutamine lowers central venous and pulmonary artery wedge pressures, 
increases cardiac output and alleviates congestive heart failure symptoms; 
however, it can also lead to arrhythmia at high dosages. It is commonly used 
following heart surgery, as well as for patients, who are suffering a heart attack 
or are in various states of shock [84]. In paediatric patients (neonates), dobuta-
mine is used to treat circulatory compromise, for example in the case of septic 
shock or after birth asphyxia, as well as to support the transitional circulation in 
very preterm infants [85].  
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2. AIMS OF THE STUDY 
The general aim of this dissertation was to further research and expand the 
selection of different novel eluent additives (such as fluorinated compounds) for 
bioanalysis using LC-MS or HPLC-UV/Vis systems and to study their influence 
on analyte retention on different stationary phases, as well as ionisation effi-
ciency (in the case of MS detection). 
This objective was achieved through: 
• evaluating the suitability of novel eluent additives for analysis using LC-MS 
and/or HPLC-UV/Vis systems 
• comparing novel eluent additives and the conventionally used buffer com-
positions  
• investigating the retention mechanisms for acidic and basic analytes within 
different column stationary phases, eluent additives and eluent pH values 
• conducting a practical application of the novel eluent additives in bio-
analytics. 
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3. EXPERIMENTAL 
3.1. Reagents 
Analytes  
4-nitrobenzoic acid, 4-dimethylaminopyridine, diphenylguanidine, 2,4-dichloro-
phenol, 2,3,4,5,6-pentafluorophenol, 2-nitrophenol, 2,3,5,6-tetrafluorophenol, 
phenol, p-cresol, hydroquinone, 3-nitroaniline, 4-chloro-2-nitroaniline, diiso-
propylamine, piperidine, cyclohexylamine, pyrrolidine, aniline, 4-chloroaniline, 
1-naphthylamine, histamine, 4-fluoroaniline, 2,6-dimethylpyridine, 2-methyl-
pyridine and 2-methoxypyridine were obtained from Sigma-Aldrich (Missouri, 
USA). The following compounds and their respective stable isotope labelled 
internal standards (IS): M3G, M6G, morphine, clonidine, MiOH, midazolam, 
M3G-D3, M6G-D3, morphine-D6 and MiOH-D4 were purchased from Ceril-
liant (Texas, USA). Clonidine-D4 and midazolam-D6 were obtained from the 
Toronto Research Chemicals Inc. (Toronto, Canada). Milrinone (United States 
Pharmacopeia Reference Standard) and dobutamine hydrochloride (United 
States Pharmacopeia Reference Standard) were obtained from Sigma Aldrich 
(Missouri, USA). Internal standard (IS) dobutamine-D4 hydrochloride was ob-
tained from Toronto Research Chemicals (Ontario, Canada) and milrinone-D3 
from TLC Pharmaceutical Standards (Ontario, Canada).  
Pregabalin, gabapentin, levetiracetam, zuclopenthixol, aripiprazole, glicla-
zide, cyclizine hydrochloride, naloxone hydrochloride dihydrate, quinine, ate-
nolol, bisoprolol, cetirizine dihydrochloride, chlorpheniramine maleate salt, 
chlorprothixene hydrochloride, diclofenac sodium salt, diltiazem hydrochloride, 
mirtazapine, naproxen, norsertraline hydrochloride solution, phencyclidine 
hydrochloride, procyclidine hydrochloride, propranolol hydrochloride were 
obtained from Sigma-Aldrich (Missouri, USA). 
LC/MS toxicology submixes: 2, 3, 4, 6, 9A, 9B, 9C and 9D were obtained 
from Agilent Technologies, Inc. (USA) 
 
Eluent additives 
1,1,1,3,3,3-hexafluoro-2-propanol (HFIP), 1,1,1,3,3,3-hexafluoro-2-methyl-2-
propanol (HFTB), 2,2,2-trifluoroethanol (TFE), 1,1,1,4,4,4‐hexafluoro‐2,3‐
bis(trifluoromethyl)butane‐2,3‐diol (PP), 1,1,1,3,3,3-hexafluoro-2-trifluoro-
methyl-2-propanol (NFTB), dimethyl sulfoxide (DMSO), ammonium fluoride 
(NH4F), formic acid, ammonium acetate, ammonium bicarbonate and a 25% 
NH4OH solution were LC-MS grade and obtained from Sigma-Aldrich (Mis-
souri, USA). IonHance™ DFA was kindly donated by the Waters Corporation. 
 
Other 
Both LC-MS grade and LC-MS Ultra grade MeOH were obtained from Sigma 
Aldrich (Missouri, USA), the water was purified (18.2 MΩ·cm at 25 ⁰C and the 
total organic carbon (TOC) value 2–3 ppb) in-house using a Millipore Advan-
tage A10 system from Millipore (Bedford, USA). The water used for experi-
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ments with LC-QTOF was LC-MS grade purchased from Fisher Chemical 
(Fisher Scientific, Waltham, USA). Ascorbic acid (reagent grade) was obtained 
from Sigma Aldrich (Missouri, USA). The plasma and whole blood were 
purchased from the Blood Bank of Tartu University Hospital. 
 
 
3.2. Instrumentation:  
chromatographic conditions and detection 
 3.2.1. Shimadzu LCMS-2020 system [IV] 
Chromatographic conditions 
The Shimadzu LCMS-2020 system (Shimadzu Corporation, Japan) consisted of 
an autosampler SIL-30AC (set at 4 oC), a binary pump LC-20AD-XR, and a 
column compartment CTO-20AC at 40 oC as well as MS and PDA detectors. 
Before conducting the experiments, the column was equilibrated for 1.5 h, using 
the chosen aqueous solution with eluent additive/buffer for the experiment. The 
elution mode was isocratic elution, with 25% of MeOH at the flow rate of  
0.2 mL/min for the C18 column (Agilent Zorbax RRHD Extend C18 (2.1 ×  
100 mm, 1.8 µm), resistant to the pH range from 2.0 to 11.5 (Agilent Techno-
logies, Inc. USA)). The column was thermostated at 40 oC. The analysis run 
time was determined depending on the analyte. For all experiments, the injec-
tion volume of the sample was 5 µL. 
 
Detection  
Both PDA and MS detectors were employed for the detection of the analytes. 
The chosen detection mode (only MS, only UV/Vis or both MS and UV/Vis) 
depended on the analyte. Shimadzu (Shimadzu Corporation, Japan) PDA 
detector (SPD-M20A model), recorded between 190 to 700 nm (600±50 nm as 
a reference wavelength); however, the extracted 254±2 nm wavelength was 
used for UV chromatograms. The MS operated in scanning mode, with the 
mass-to-charge (m/z) ranges depending on the analytes in question  
(m/z 150–700 for the analysis of eluent additives, m/z 50–200 for analytes,). The 
interface temperature was 350 ⁰C, DL temperature 250 ⁰C, heat block 
temperature 200 ⁰C. Nebulising gas flow was 1.5 L/min and drying gas flow 15 
L/min. Both positive and negative ion modes were used. The analytes were 
detected either as [M+H]+ or [M-H]-. 
 
 
3.2.2. ABSciex API 4000 system [IV] 
The TFE MS spectrum was obtained with an ABSciex API 4000 (AB Sciex Pte 
Ltd, Australia), using negative ionisation. The MS was set to a scanning mode 
between m/z 40–120. The solution infused with the flowrate 10 uL/min was 1% 
TFE in a H2O/MeOH mixture (50/50, v/v) with 0.1 % NH4OH. 
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3.2.3. Agilent 1200 Infinity LC system [IV] 
The Agilent 1200 Infinity LC system (Agilent Technologies, Inc. USA) con-
sisted of an autosampler, a binary pump, and a UV/Vis detector with 5-
channels. Chromatograms were recorded at 254±2 nm wavelength (using 
360±50 nm as a reference wavelength). 
The column in use was Agilent ZORBAX Extend C18 (2.1 × 100 mm, 3.5 μm) 
and was reported to be resistant between pH 2.0 to 11.5 by the manufacturer 
(Agilent Technologies, Inc., USA). The column was equilibrated for 1.5 h, 
using the aqueous solution with an eluent additive/buffer depending on the 
following experiments. The flow rate used was 0.5 mL/min, with isocratic elu-
tion with 25% of MeOH. The column was kept at room temperature. For all 
experiments, the analysis run time was determined depending on the analyte 
and the injection volume of the sample was 5 µL.  
 
 
3.2.4. Agilent Infinity II 1290 LC system with  
Agilent Ultivo mass spectrometer 
Chromatographic conditions 
The Agilent Infinity II 1290 LC system consisted of an autosampler, a binary 
pump and a mini MS detector Ultivo (Agilent Technologies, Inc., USA). Before 
experiments, the column was equilibrated for 1.5 h, using the chosen eluent. The 
elution mode was isocratic, with 25% of MeOH at the flow rate of 0.5 mL/min. 
The column used was Kinetex Biphenyl (2.1 × 100 mm, 2.6 μm), resistant to the 
pH range from 1.5 to 10 under isocratic conditions (Phenomenex Inc. USA). 
The column was thermostated at 40 oC. The analysis run time was determined 
depending on the analyte. For all experiments, the injection volume of the 
sample was 5 µL. 
 
Detection 
The Agilent Ultivo MS was used for the detection of the analytes. The MS 
operated in scanning mode, with the m/z ranges depending on the analytes in 
question (m/z 150–700 for the analysis of eluent additives, m/z 50–200 for 
analytes). The simultaneous positive and negative ion detection mode was used. 
The analytes were detected either as [M+H]+ or [M-H]-. 
 
 
3.2.5. Agilent Infinity II 1290 LC system with 
 Agilent QTOF 6545B mass spectrometer 
Chromatographic conditions 
The Agilent with QTOF 6545B (Agilent Technologies, Inc. USA) system con-
sisted of a thermostated column compartment, a binary pump and an isocratic 
pump (used in the flow rate 1 mL/min, with a splitter for a dual-probe ion 
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source), and an autosampler (kept at 4 °C). Analytical columns with three diffe-
rent stationary phases were used: 
• Agilent ZORBAX Eclipse Plus C18 (2.1 × 100 mm, 1.8 μm) resistant to 
the pH range from 2–9 (Agilent Technologies, Inc. USA); 
• Kinetex Biphenyl (2.1 × 100 mm, 2.6 μm) resistant to the pH range from 
1.5–10 (Phenomenex Inc. USA); 
• Restek Raptor FluoroPhenyl (PFP) resistant to the pH range from 2.0–8.0 
(2.1 × 100 mm, 2.7 μm) (donated by Restek Corporation, USA). 
The column compartment was maintained at 40 °C. The eluents (both phases A 
and B) were composed depending on the analysis (Table 2). If needed, the pH 
was adjusted with a 20% NH4OH solution. 
 
 
Table 2. The eluent composition used with different analytical columns. 
Column Aqueous phase A Organic phase B 
C18 
5 mM ammonium formate and 0.01% 
formic acid (v/v) 
MeOH with 5 mM 
ammonium formate and 
0.01% formic acid (v/v) 
5 mM ammonium formate and 0.01% 
DFA (v/v) 
MeOH with 5 mM 
ammonium formate and 
0.01% DFA (v/v) 
0.15% DFA (v/v) MeOH 
Biphenyl 
5 mM ammonium acetate (v/v), pH 8.5 
MeOH 5 mM ammonium acetate (v/v), pH 9.0 5 mM HFTB (v/v), pH 8.5 
5 mM HFTB (v/v), pH 9.0 
PFP 
5 mM ammonium formate and 0.01% 
formic acid (v/v), pH 4.0 MeOH 5 mM HFTB (v/v), pH 8.5 
5 mM HFTB (v/v), pH 9.0 
 
 
The gradient elution patterns can be seen in Table 3 (with 1 min post time). The 
used flow rate was 0.400 mL/min. 
 
 
Table 3. The gradient programme for the separation of the analytes included in the 
toxicology screening experiments. 
Time, min Aqueous phase 
A, % 
Organic phase B 
(MeOH), % 
0 95 5 
1 95 5 
10 0 100 
12 0 100 
12.1 95 5 
13 95 5 
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Detection 
Agilent QTOF 6545B mass spectrometer (Santa Clara, USA) was used for the 
detection of the analytes. The spectral data was recorded with these parameters: 
positive ion scan (30 V) with scan-rate 3 and the m/z scanning range  
m/z 40–1000. Through the dual-probe ion source a reference ion solution (with 
ions m/z 121.0509 and 922.0098) was delivered to ensure mass accuracy. The 
data were compared against in-house standard drug and metabolite libraries, 
which contain MS/MS spectra, empirical formulae, and retention times from in-
house reference standards.  
The following mass analyser settings were used: drying gas flow rate  
12 L/min, drying gas temperature 250 °C, nebuliser pressure 35 psi (0.241 
MPa), sheath gas flow (12 L/min) and sheath gas temperature 350 °C, nozzle 
voltage (300 V) and capillary voltage (3,500 V), fragmentor voltage (150 V), 
skimmer voltage (65 V) and Oct 1 RF Vpp (750 V). 
 
 
3.2.6. Agilent 1290 Infinity UHPLC system with Agilent 6495 
Triple Quadrupole mass spectrometer [I, III, V, VI] 
Analysis of morphine, clonidine and midazolam and their metabolites [I] 
A detailed description of the chromatographic conditions and detection for the 
analysis of three sedative drugs (morphine, clonidine and midazolam) and their 
metabolites (M3G, M6G and MiOH) can be found in the paper [I]. 
 
Analysis of milrinone and dobutamine [III; V; VI] 
A detailed description of the chromatographic conditions and detection for the 
analysis of two cardiovascular drugs (milrinone and dobutamine) can be found 
in the paper [III]. 
 
3.3. Methods  
3.3.1. Methods for the retention mechanism studies [IV] 
Stock solution and working standard solution preparation  
Aqueous working standard solutions were prepared in varying concentrations 
from 0.1, 10 to 50 µg/mL – depending on the analyte. All analyte standard solu-
tions were prepared in either 0.1 % formic acid and 1 mM ammonium acetate in 
H2O/MeOH (8/2, v/v) solution (experiments for C18 columns) or H2O/MeOH 
(8/2, v/v) solution (experiments with biphenyl columns). All prepared standard 
solutions were filtered using a 0.45 µm regenerated cellulose filter (Captiva 
Econofilter, Agilent Technologies, Inc., USA) prior to injection to the LC-MS 
system. 
Solutions for the eluent additives retention experiments were prepared with 
the concentration of a 0.1% eluent additive (HFIP, HFTB, PP and NFTB) in 
water (v/v). 
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Buffer composition 
An aqueous standard buffer (STD) was prepared with the final concentration of 
0.1% formic acid and 1 mM ammonium acetate in water. The pH of the STD 
buffer was 2.8. 
All other aqueous solutions with eluent additive/buffers used for the reten-
tion mechanism studies (ammonium bicarbonate, ammonium acetate, NH4F, 
HFTB, HFIP, DMSO, PP, NFTB and TFE) had the concentration of 5 mM of 
the eluent additive (in water). The required pH (8.5, 9.0 or 10.0) was reached 
with the addition of a sufficient amount (depending on the eluent additive) of 
NH4OH solution in water. The buffers containing DFA were prepared, as shown 
in Table 2. 
 
Dead time acquisition and column’s performance 
In order to continuously monitor the column’s performance and to obtain the 
value of dead time (t0), a mixture of analytes (acetophenone, acetone, benzene, 
naphthalene and toluene) was injected into the system. The t0 was recorded as 
the retention time of the acetone peak, and the value was obtained as the 
average retention time from further subsequent injections. 
The manufacturers recommendations for the best handling of a column were 
noted. However, since the research focused on expanding the knowledge of 
retention mechanisms in high pH environment, it was not always possible to 
adhere to those limitations.  
 
Experimental solvent-water pH ( 𝒑𝑯𝒘𝒔 ) and pHabs measurements in mobile 
phases 
Along with the conventional  pH୵୵  values, also the ( pH୵ୱ ) and pHabs values were 
measured. For the pH୵ୱ  measurements, a Mettler Toledo InLab Micro  
pH-electrode was used. Before every measurement series, two-point calibration 
was done, using buffer solutions at pH 7 and pH 10.  A glass beaker with a 
magnetic stirrer and 50 mL of the mobile phase (75% aqueous solution with 
eluent additive, 25% MeOH, v/v), was covered with a polystyrene foam cap (to 
avoid evaporation). All mobile phases were measured at least twice and in 
random order. During the series, also calibration buffer solutions were 
remeasured to evaluate drift. The standard deviation of all pH୵ୱ  measurement 
results was 0.05 pH units, which indicates good consistency. The pH୵ୱ  readings 
of the mobile phases for two eluent additives – DMSO and TFE exhibited 
considerable drift, so readings were taken after a constant time (5 min) from the 
immersion of the electrode. 
A detailed method description of measuring the pHabs and anchoring the 
pH୵ୱ  measured values can be found in [IV]. 
In this dissertation, when the term pH is mentioned, it refers to the aqueous 
phase pH ( pH୵୵ ), unless stated otherwise. 
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3.3.2. Separation of common toxicology  
screening compounds   
Preparation of a working standard solution 
All analytes in the concentration 0.1 µg/mL were prepared by the appropriate 
dilution of previously made sub-stocks (with a concentration 1–100 mg/mL) 
with MeOH and an LC-MS grade water mixture 20/80 (v/v).  
 
 
3.3.3. Analysis of morphine, clonidine and  
midazolam and their metabolites [I]  
A detailed description of the preparation of stock solutions, calibrators, quality 
control and real samples for the analysis of three sedative drugs (morphine, 
clonidine and midazolam) and their metabolites (M3G, M6G and MiOH) can be 
found in the paper [I]. 
 
 
3.2.4. Analysis of milrinone and dobutamine [III]  
A detailed description about of the preparation of stock solutions, calibrators, 
quality control and real samples for the analysis of two cardiovascular drugs 
(milrinone and dobutamine) can be found in the paper [III].  
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4. RESULTS AND DISCUSSION 
4.1. Retention mechanisms in standard solutions 
4.1.1. The set of model analytes on various  
RP stationary phases 
 
In order to research how novel eluent additives influence analyte retention in 
different reversed-phase analytical columns, a simple set of analytes with 
different functional groups, pKa and logP values were chosen. On the basis of 
these criteria, the analytes were divided into groups (Figure 5): acids (AH) and 
bases (B). The two main groups were then further divided into four subgroups, 
depending on the form in which the analyte is (predominantly) present at the 
researched eluent pH, in the range of 8.5 to 10.0: either as ionised analytes (A- 
or BH+) or non-ionised/neutral (AH or B) analytes. 
 
 
Figure 5. The selection of analytes for retention mechanism studies and the division of 
the analytes into groups and sub-groups based on their acidic and basic properties. 
 
 
Furthermore, the measurements of the pH, after the addition of methanol were 
carried out, so see how well the pH୵୵  correspond after the addition of the 
organic phase – MeOH ( pH୵ୱ ). As presented in Table 4, for eluent the additives 
ammonium acetate and bicarbonate, HFIP, HFTB and PP no value has larger 
difference than 0.35 units.  
 
  
Acids
Deprotonated acids (anionic) with pKa < 7 (A- at high pH)
Protonated acids (neutral) with pKa > 10 (AH at high pH)
Bases
Protonated bases (cationic) with pKa> 10 (BH+ at high pH)
Deprotonated bases (neutral) with pKa < 7 (B at high pH)
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Table 4. Results of the pH୵ୱ  (the pH of the eluent consisting of 75% aqueous solutions 
with eluent additive, 25% MeOH, v/v) and pHabs measurements.  
Eluent additive 𝐩𝐇𝐰𝐰  𝐩𝐇𝐰𝐬  pHabs pHabs – 𝐩𝐇𝐰𝐰  
Ammonium acetate 8.50 8.39 8.17 -0.33 
Ammonium acetate 9.00 8.92 8.70 -0.30 
Ammonium acetate 10.00 9.91 9.69 -0.31 
Ammonium bicarbonate 8.50 8.56 8.35 -0.15 
Ammonium bicarbonate 9.00 9.01 8.80 -0.20 
Ammonium bicarbonate 10.00 10.01 9.79 -0.21 
HFIP 8.50 9.05 8.83 0.33 
HFIP 9.00 9.39 9.18 0.18 
HFIP 10.00 10.08 9.87 -0.13 
HFTB 8.50 9.07 8.85 0.35 
HFTB 9.00 9.42 9.20 0.20 
HFTB 10.00 10.15 9.94 -0.06 
PP 8.50 8.42 8.20 -0.30 
PP 9.00 8.90 8.68 -0.32 
PP 10.00 9.93 9.71 -0.29 
 
 
The full data set of the measured retention factors is accessible via the supple-
mentary material of paper [IV]. Data were gathered for 25 analytes (Table 5). 
Out of those, 13 were not ionised at the researched pH values: eight were pre-
dominantly neutral basic analytes (B) and five were predominantly neutral 
acidic analytes (AH). Eleven analytes were predominantly ionised – five de-
protonated acidic analytes (A-) and six protonated basic analytes (BH+). One 
analyte, due to possessing two functional groups and two pKa values, falls under 
both the B and BH+ groups.  
From the whole data set, the interaction between three analytes (4-nitro-
benzoic acid, 4-dimethylaminopyridine and diphenylguanidine) and PP and 
NFTB eluent additives were studied with a C18 column.  
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4.1.2. Retention mechanisms on  
the C18 stationary phase [IV] 
4.1.2.1. Changes in analyte retention  
Conventional eluent additives (ammonium acetate and ammonium 
bicarbonate) 
For the predominantly deprotonated acids (the A- group, analytes with  
pKa <7.9), a consistent overall decrease in the retention factors with an increase 
of the pH (Figure 6) was observed. The reason for the shorter retention factors 
is the shift in the equilibria between the analyte’s deprotonated form A- (which 
is in the majority, at the researched eluent pH) and that of the neutral AH form. 
The amount of the AH form decreases with the increase of the pH, which results 
in the analyte being poorly retained on the C18 phase. Overall, the retention 
factors obtained with the ammonium bicarbonate were shorter than those 
obtained when ammonium acetate was used as the eluent additive. The diffe-
rence arises due to slightly higher pH୵ୱ  values of the ammonium bicarbonate 
buffer (Table 4), which means even lesser part of the analyte is in the AH form 
and therefore is retained less. 
 
 
Figure 6. Retention factors of the analytes from the deprotonated acidic (A-) group 
when using ammonium acetate and bicarbonate as eluent additives at the pH values of 
8.5, 9.0 and 10.0. 
 
 
As for neutral acids (the AH group, analytes with pKa >9.9), the retention 
factors somewhat decreased with the increase in the pH; however, no significant 
difference was observed between the eluent additives (Figure 7). The decrease 
in retention may indicate a decrease in the analyte’s AH form (as the pKa values 
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of the majority of the analytes were around 10), therefore the analyte becomes 
more polar and is less retained on the non-polar C18 stationary phase.  
 
 
 
Figure 7. Retention factors of the analytes from the neutral acidic (AH) group when 
using different eluent additives at the pH values of 8.5, 9.0 and 10.0. Due to a very low 
retention factor values for hydroquinone, also the numerical values are shown. 
 
 
The same as the acids in the AH neutral group, also the neutral basic analytes 
(B group, analytes with pKa ≤6.6) showed stable retention factors across the 
three researched eluent pH values (Figure 8). When ammonium bicarbonate was 
used as the eluent additive, the variation in retention times was higher; however, 
no clear relationship could be observed. 
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Figure 8. Retention factors of the analytes from the neutral basic (B) group when using 
both conventional (ammonium acetate and bicarbonate) and novel (HFIP, HFTB) eluent 
additives at the pH values of 8.5, 9.0 and 10.0. 
 
 
For the basic polar analytes’ group (BH+, analytes with pKa ≥9.6), an increase in 
the retention factors was observed with an increase in the pH (Figure 9). Both 
conventional buffers (especially ammonium acetate) had a steep increase (4–8 
times) in retention factors when comparing values obtained at eluent the pH 9.0 
and 10.0. This “jump” can be explained by the change in the majority of 
analyte’s form – to B at the pH 10.0 (which is close to the analyte’s pKa), while 
at the pH 8.5 and 9.0, the larger part (if not all) of the analyte was in its 
protonated form BH+, thus polar and poorly retained. Ammonium acetate 
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showed slightly lower retention factors than those obtained with ammonium 
bicarbonate. The difference in retention can again be explained with difference 
in pH୵ୱ  values (Table 4) for ammonium acetate and bicarbonate buffers. A 
higher pH୵ୱ  (in case of ammonium bicarbonate) means larger part of analyte is 
in B form and thus is retained more on in C18 column. 
 
 
Figure 9. Retention factors of the analytes from the protonated basic (BH+) group when 
using ammonium acetate and bicarbonate eluent additives at the pH values of 8.5, 9.0 
and 10.0. 
 
 
Fluoroalcohols HFIP and HFTB 
When compared to commonly used eluent additives (ammonium acetate and 
bicarbonate), the retention factors obtained when using HFIP and HFTB as 
eluent additives created different trends for different analytes and analyte 
groups. The main trends observed (for the same analyte) were also different 
between HFIP and HFTB (unlike when ammonium acetate and bicarbonate 
were used).  
Overall, lower retention factors were seen compared to conventional eluent 
additives (Figure 10) in the deprotonated acid (A-) group and mostly a decrease 
in the retention factors with an increase in the pH was observed). Both of the 
two analytes – fluorinated phenols – 2,3,4,5,6-pentafluorophenol and 2,3,5,6-
tetrafluorophenol – have similar hydrophobicity and the same pKa value (5.53). 
Thus, they also display similar behaviour and retention factors. For both 
analytes, using HFIP as the eluent additive decreased their retention factors by 
2–4 times and when HFTB was used as the eluent additive, the retention factors 
decreased by 1.4–6 times when compared to ammonium acetate at the same pH 
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value. The overall decrease in retention for acidic analytes, especially those 
which are ionised, has been observed by Kipper et al. [25]. This supports the 
proposed theory that acidic analytes both compete with novel eluent additives 
for a place on the stationary phase and are repelled by the fluorous phase that 
novel eluent additives create on top of the stationary phase. Furthermore, 
decrease in retention with increase of the pH of mobile phase arises due to pKa 
values of HFIP and HFTB. As acidic analytes larger fraction of HFIP and 
HFTB becomes deprotonated and thus increasingly repulsed to already 
deprotonated acidic analytes. 
 
 
Figure 10. Retention factors of the analytes from the deprotonated acidic (A-) group 
when using both conventional (ammonium acetate and -bicarbonate – greyed out as the 
data were already presented in Figure 6 and were added here as comparison) and novel 
(HFIP, HFTB) eluent additives at the pH values of 8.5, 9.0 and 10.0. 
 
 
As for the neutral acidic analyte group AH, similarly to the conventional eluent 
additives – ammonium acetate and bicarbonate (Figure 7) – also novel 
fluorinated eluent additives HFIP and HFTB presented no clear trend of 
decrease or increase in the retention factors (Figure 11), even if the retention 
factors presented a larger variation between different eluent pH values. Overall, 
with fluorinated additives a decrease in the retention factors was observed. This 
implies that the previously mentioned relationship of competition between the 
acidic analytes (more apparent in the A- group, Figure 6 and Figure 10) and 
novel fluoro-alcoholic eluent additives also apply in the case of analytes, which 
are either in the neutral form or ionised only to a small degree.   
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Figure 11. Retention factors of the analytes from the neutral acidic (AH) group when 
using both conventional (ammonium acetate and -bicarbonate – greyed out as the data 
were already presented in Figure 7 and were added here as comparison) and novel 
(HFIP, HFTB) eluent additives at the pH values of 8.5, 9.0 and 10.0. Due to the very 
low retention factor values for hydroquinone, also the numerical values are shown. 
 
 
In the case of the neutral basic analytes group (B, Figure 8), neither a significant 
change in the retention factor nor any trends were apparent when HFIP and 
HFTB were used as eluent additives. The only analyte from the group, which 
displayed a clear trend of increase in the retention factors with an increase of the 
pH, only when HFTB was used as the eluent additive, was the strongest basic 
analyte – 2,6-dimethylpyridine (pKa 6.60) from the B analyte group. 
Most of the analytes from the protonated bases group (BH+) displayed a 
significant increase in the retention factors with the increase of the eluent pH 
(Figure 12), as well as presented visually significant differences in elution 
patterns between different eluent additives. This can be explained by both a 
change of the mobile phase pH and the ion-pairing properties of fluoroalcohols. 
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Figure 12. Retention factors of the protonated basic (BH+ group) analytes when HFIP 
and HFTB eluent additives are used and the pH is changed from 8.5 to 10.0 as 
compared to common eluent additives (ammonium acetate and -bicarbonate – greyed 
out as the data were already presented in Figure 9 and were added here as comparison). 
 
 
Both HFIP and HFTB strongly increased retention for the protonated basic 
group (BH+) analytes, when compared to ammonium acetate or carbonate at the 
same pH values. When HFIP is compared to HFTB, the latter demonstrated 
larger retention factors. The most significant difference in the retention factors 
was observed for cyclohexylamine – an analyte, which is the weakest base in 
the group (has the smallest pKa,). For cyclohexylamine, the retention factor 
increased by 28 times when HFIP was used and by 35 times when HFTB was 
used as the eluent additive at the pH 9.0 when compared to the retention factors 
of ammonium acetate at the same pH.  
  
DMSO and fluoroalcohol TFE 
Aqueous solutions made with either TFE or DMSO as eluent additives had very 
little to no buffering capacity. Thus, TFE and DMSO solutions needed a mini-
mal amount of NH4OH to reach the needed pH values of 8.5 and 9.0. Initially, 
the main cause for the instability of the pH over time was deemed to be the 
evaporation of NH4OH, and thus, the average stability of the pH for the 
DMSO/TFE solutions was evaluated (with measurements of the pH over time) 
to be no more than 3 hours. However, the main cause of the change in the pH, 
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as well as inexplicable results, was the addition of an organic solvent. It 
changed the pH୵ୱ  dramatically, as shown in Table 6.  
 
 
Table 6. Results of the pH୵ୱ  (the pH of the eluent consisting of 75% aqueous solutions 
with an eluent additive, 25% MeOH, v/v) and pHabs measurements. The concentration 
of the eluent additive in the water solution was 5 mM. 
Eluent additive 𝐩𝐇𝐰𝐰  𝐩𝐇𝐰𝐬  pHabs pHabs – 𝐩𝐇𝐰𝐰  
DMSO 8.50 7.68 7.46 -1.04 
DMSO 9.00 7.62 7.40 -1.60 
DMSO 10.00 9.92 9.70 -0.30 
TFE 8.50 7.45 7.23 -1.27 
TFE 9.00 7.59 7.38 -1.62 
TFE 10.00 9.94 9.73 -0.27 
 
 
Both DMSO and TFE essentially behave as neutral compounds at the re-
searched eluent pH values. This is different from other researched eluent addi-
tives, which behave as acids. Therefore, DMSO and TFE cannot form a buffer 
solution, and the only buffering capacity was dependent on the small amounts 
of added NH4OH. Since the pH୵୵  and pHabs values of these mobile phases 
should be considered as dubious, DMSO and TFE are not suited as eluent 
additives for researching and use as basic buffers with pH୵୵  values below 10. 
 
Novel fluoroalcohols: perfluoropinacol (PP) and NFTB 
In parallel, also two additional promising fluorinated eluent additives: PP and 
NFTB were studied for a smaller set of analytes. For protonated basic (BH+) 
analytes, PP demonstrated a dramatic increase in retention (Figure 13). At the 
pH 8.5, diphenylguanidine was retained 41 for times longer than when PP was 
used as the eluent additive (in comparison to ammonium acetate). Additionally, 
diphenylguanidine’s retention decreased at the pH 10.0, which is not the 
expected relationship for a basic protonated analyte. The likely reason for this is 
structural differences – unlike HFIP, HFTB and NFTB, which have one 
hydroxy group, the PP has two, and thus also two pKa values. At the pH 8.5 and 
9.0, the majority of perfluoropinacol in the eluent is in a monoanionic form 
(because the pKa1 value is 5.95 in water). Since PP’s second (pKa2) value is 
10.42 (in water), it can be assumed that, at the pH 10.0, the second OH group 
undergoes the loss of a proton, at least partially. Diphenylguanidine’s pKa value 
is 10.12. At the pH 10.0 also the amount of its deprotonated form increases and 
thus becomes less attracted to the increasingly anionic PP at pH 10.0. 
As for other analyte groups, the relationships observed fell in line with 
previous conclusions: analytes in the deprotonated acid (A-) group had a 
decrease in the retention factors with an increase in the mobile phases’ pH. In 
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contrast, the retention factors of neutral analytes (AH and B groups) remained 
constant and similar to the values obtained with the ammonium acetate buffer. 
 
 
Figure 13. Retention factors of the protonated basic (BH+ group) analytes when PP and 
NFTB eluent additives are used, and the pH is changed from 8.5 to 10.0. Novel eluent 
additives are compared with the common eluent additive ammonium acetate. 
 
When NFTB was used, diphenylguanidine showed an increase in the retention 
factors by 8 times – (at the eluent’s pH 8.5). The large increase in the retention 
factors was also observed for 4-dimethylaminopyridine (Figure 13). Since PP is 
retained on the C18 analytical column to a much larger extent than NFTB 
(which elutes at the beginning of a chromatographical run, Figure 20), it can be 
theorised that PP (the same as HFIP and HFTB) create a fluorous layer on the 
stationary phase. 
 
 
4.1.2.2. Analyte ionisation efficiency  
For the analytes, which were detected with an MS, signal intensity changed 
using different eluent additive buffers. However, the differences (observed by 
comparing peak areas, Figure 14 and Table 7) depended highly on the analyte, 
eluent additive and the pH studied. As the focus of research was different reten-
tion mechanisms, the MS signal intensities (presented as single measurement 
peak areas) are provided as additional information to give general impression. 
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As already stated, the recorded signal varied greatly between analytes, eluent 
additives and the mobile phase pH. When comparing eluent additives, in 
general, the largest signals were observed for ammonium bicarbonate-based 
eluents. This was true for analytes diisopropylamine, pyrrolidine, piperidine, 
and histamine.  
At low pH (STD buffer), the studied basic analytes should be present in the 
protonated BH+ form and should be very well ionised. This is true for the 
analytes in B group, but not for the BH+ group analytes – they yield much 
higher signals when mobile phase pH is also high. This observed effect is an 
example of so-called wrong-way ionisation [87]. 
As ammonium acetate is one of the most commonly used eluent additives, it 
was used as a point of reference for the comparison of analyte signal responses. 
When novel eluent additives HFIP and HFTB were used (at the same pH 
values), it showed that in 26% of the measurements, there was an increase in the 
signal (with a range between 1.1 to 36-fold). However, rest of the results 
showed decrease (up to <10% of signal) in the peak area of the analytes of the 
area obtained with ammonium acetate.  
The majority of the increased signal was observed for ionised basic (BH+) 
analytes when ammonium bicarbonate, HFIP and HFTB were used. Because the 
BH+ group analytes are already protonated in solution, they are more easily 
converted into gas-phase ions and thus in general have better signal than others. 
The largest increase was obtained for cyclohexylamine using HFIP, at the pH 
9.0 (36-fold), however, for the same analyte – with other HFIP buffer pH values 
(8.5 and 10.0), the signal was lower than when ammonium acetate was used at 
respective pH levels.  
DMSO as the eluent additive resulted in significant signal suppression – no 
peaks could be obtained for aniline, 4-chloroaniline, 1-napthylamine and  
2-methoxypyridine. Both DMSO and TFE gave the lowest signals when com-
pared to other eluent additives.  DMSO has been reported as having a positive 
influence on the signal intensity in MS; however so far it seems this is observed 
only in the field of proteomics [32]–[34]. Furthermore, due to the high boiling 
point of DMSO, the default used ion source parameters, uniform for all analytes 
and eluent additives, are possibly not optimal for DMSO. TFE has been 
reported to both increase [26], [88] the analyte signal and suppress it for oligo-
nucleotides [89]. However, the signal enhancement for (hydrophobic) com-
pounds was observed in the working ESI in the negative detection mode or in 
the presence of other ion-pairing reagents. Additionally, the decreased signal 
response was observed in these cases for more hydrophilic analytes. [26], [88]  
In conclusion – in general higher ionisation efficiency can be obtained with 
the high pH mobile phases for polar basic analytes and using HFIP and HFTB, 
however more rigorous experiments should be conducted to obtain more 
specific conclusions.  
 
52 
4.1.3. Retention mechanisms on  
the biphenyl stationary phase 
The changes in the retention of the analytes on biphenyl columns due to the 
change of the eluent additive and shift in the eluent pH tended to follow similar 
patterns as seen previously for the C18 column (Table 8). The patterns were: for 
non-ionised analytes (such as AH and B at a high mobile phase pH), the 
retention is not significantly influenced by the change of the eluent pH or eluent 
additive. For the ionised acidic analytes (A- group) the retention decreased with 
the increase in the pH and decreased further when novel fluorinated eluent 
additives were used. For protonated (polar) basic analytes (BH+), the influence 
was opposite to acidic analytes – the retention increased with the increase in the 
pH and further increased when novel fluorinated eluent additives were used. 
Further discussion will highlight the differences in retention between the 
C18 and biphenyl stationary phases among the four different analyte groups.  
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The deprotonated acids (polar) analyte group 
The relationship – decrease in retention with the increase in the pH and a further 
decrease in retention when HFIP and HFTB were used as eluent additives 
(Figure 10) remain the same for both the C18 and biphenyl columns.  
Two similar A- group analytes (2,3,4,5,6-pentafluorophenol and  
2,3,5,6-tetrafluorophenol) are far less retained with biphenyl column (Figure 
15). The largest difference in the retention factors appear when HFTB is used as 
the eluent additive, at the eluent pH 8.5. For 2,3,4,5,6-pentafluorophenaol, 
retention decreased 26 times and for 2,3,5,6-tetrafluorophenaol it decreased 14 
times. The halogen and π-bond interaction has been described in the literature 
with the help of the σ-hole [90] – as intermolecular interaction between an 
electron-rich aromatic ring and an electron-poor region of bonded halogen [91], 
it should present itself also in the case of the biphenyl column. Likewise, the 
biphenyl column has high hydrogen-bond capacity. However, it seems that the 
ionic interaction of the negatively charged analyte has a more substantial 
influence on retention.  
 
 
 
Figure 15. Obtained retention factors with the C18 and biphenyl analytical column for 
2,3,4,5,6-pentafluorophenol and 2,3,5,6-tetrafluorophenol using both conventional 
(ammonium acetate and bicarbonate) and novel (HFIP, HFTB) eluent additives at the 
pH values of 8.5, 9.0 and 10.0. 
 
For the analyte 2-nitrophenol the increase in the retention factors was observed 
when ammonium bicarbonate was used as the eluent additive at the pH 8.5 and 
9.0, but lower retention factors when the biphenyl column was used at all other 
eluent and pH combinations (Table 8). For 2,4-dichlorophenol, a large increase 
in the retention factor was observed (Figure 16) on the biphenyl column. Pos-
sibly having two halogen atoms (chlorine) in the molecule aided the retention of 
the basis of the halogen and π-bond attraction. 
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Figure 16. Obtained retention factors with the C18 and biphenyl analytical columns for 
2,4-dichlorophenol using both conventional (ammonium acetate and bicarbonate) and 
novel (HFIP, HFTB) eluent additives at the pH values of 8.5, 9.0 and 10.0. Due to low 
retention factor values obtained with the C18 column, also the numerical values are 
shown. 
 
The protonated acids (neutral) analyte group 
With the exception of 4-chloro-2-nitroaniline, all other – phenol (Figure 17),  
p-cresol and hydroquinone from the neutral acidic analytes (AH) group had 
larger retention when the biphenyl column was used (with the exception of 
hydroquinone when ammonium acetate was used as the eluent additive at the 
pH 10.0) due to the additional hydrogen-bond and π-π bonding. While, the 
increase was rather insignificant and remained within 1.1-1.8 times for all 
analytes, the difference between retention factors obtained with C18 and 
biphenyl column was the greatest at the eluent pH 8.5 and decreased for 
biphenyl with an increase of the pH. This is due the mobile phase pH value 
nearing the value of the analyte’s pKa. This means both for HFIP and HFTB as 
well as for acidic analyte that larger fraction of compound becomes 
deprotonated and thus polar. The repelling interactions outweigh the influence 
of π-π bonding. 
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Figure 17. Obtained retention factors with the C18 and biphenyl analytical columns for 
phenol using both conventional (ammonium acetate and bicarbonate) and novel (HFIP, 
HFTB) eluent additives at the pH values of 8.5, 9.0 and 10.0. * – no analyte peaks were 
recorded. 
 
 
The protonated (polar) basic analyte group 
All analytes in the basic protonated analyte group demonstrated an increase in 
retention factors when the biphenyl column was used (Table 8), even if none of 
the analytes had an aromatic ring (Table 5) in their structure, thus do not have 
π-π interactions on biphenyl column. However, all analytes could still act as 
both hydrogen bond donors and acceptors. The relationship – an increase in 
retention with an increase of pH of the eluent and then, further increase if HFIP 
and HFTB were used as eluent additives in comparison to conventional 
ammonium acetate and bicarbonate – remained the same as for C18 column. 
However, unlike with C18 column (Figure 9), the retention factors increased 
more gradually with the increase of eluent pH (Figure 18).  
The largest increase in retention factors (when comparing C18 to the biphe-
nyl stationary phase) was observed for analytes diisopropylamine and cyclo-
hexylamine. For cyclohexylamine, 38 times increase in retention factor was 
observed when using HFTB at pH 8.5, and 16 times increase when comparing 
ammonium acetate at pH 9.0 as eluent. For diisopropylamine largest increase: 
28 times, was observed when HFIP was used as eluent additive at pH 8.5. Both 
analytes had similar logP values – 1.49 for cyclohexylamine and 1.40 for 
diisopropylamine and thus are more lipophilic than the other 2 analytes in the 
group – piperidine (logP 0.84) and pyrrolidine (logP 0.50). Piperidine and 
pyrrolidine demonstrated an increase in retention, but in the range of 2–7 times. 
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Figure 18. Obtained retention factors with C18 and biphenyl analytical column for 
piperidine using both conventional (ammonium acetate and bicarbonate) and novel 
(HFIP, HFTB) eluent additives at pH values of 8.5, 9.0 and 10.0. 
 
The deprotonated (neutral) basic analyte group 
The deprotonated basic analyte group (B) was split – two analytes (4-chloroani-
line, and 3-nitroaniline) were more retained on the C18 column, while six ana-
lytes (aniline, 4-fluoroaniline, 2,6-dimethylpyridine, 2-methylpyridine,  
1-naphtylamine and 2-methoxypyridine) were more retained on the biphenyl 
column. However, the majority saw no greater difference in the retention factors 
than by 2 times. Exceptions to that were the analytes which were well retained 
on the C18 column – 4-chloroaniline and 3-nitroaniline, but eluted around the 
dead time when the biphenyl column was used. 
Additionally, all analytes (except 4-fluoroaniline), which were retained more 
on the biphenyl column, saw also a subtle decrease in retention times with the 
increase of the eluents’ pH (Figure 19 and Table 8). 
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Figure 19. Obtained retention factors with the C18 and biphenyl analytical column for 
1-naphtylamine using both conventional (ammonium acetate and bicarbonate) and novel 
(HFIP, HFTB) eluent additives at the pH values of 8.5, 9.0 and 10.0. 
 
Summarising remarks regarding the retention mechanisms observed on the 
biphenyl stationary phase 
Since the majority of studied simple model analytes (with the exception of four) 
have an aromatic ring in their structure (Table 5), it was expected to observe a 
larger retention due to π-π interactions between aromatic analytes. 16 analytes 
were retained more on the biphenyl stationary phase – also including those 
without an aromatic ring (from protonated basic analyte group). The five other 
analytes, which were better retained with on the C18 column, had either a nitro 
(-NO2) group in their structure (4-chloro-2-nitroanailine, 2-nitrophenol and  
3-nitroaniline) or multiple halogen atoms (2,3,4,5,6-pentafluorophenol and 
2,3,5,6-tetrafluorophenol). Both neutral analyte groups (deprotonated acids and 
protonated bases) did not have as uniform retention factors as seen before on the 
C18 column and the majority of analytes demonstrated a decrease in retention 
with an increase in the pH.  
 
 
4.1.4. Retention of eluent additives on the C18, biphenyl and 
PFP stationary phases and ionisation 
Changes in the eluent additive retention on the C18 stationary phase 
The retention of HFIP and HFTB was strongly influenced by the pH of the 
mobile phase [25]. Thus the retention of three eluent additives TFE, PP and 
NFTB on the C18 stationary phase was evaluated also at the different pH values 
8.5, 9.0 and 10.0.  
A decrease in retention time with an increase in the mobile phase’s pH was 
observed for both NFTB (Figure 20) and PP (Figure 21). NFTB saw the 
retention time change from 5.7 min at pH 8.5 to 3.5 min at the pH 10.0. The 
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change was more evident for HFIP and HFTB [25] as their pKa values are close 
to the eluent pH than pKa value of NFTB. For perfluoropinacol change in 
retention time was observed from 23.1 min at the pH 8.5 to 18.3 min at the pH 
10.0. Decrease in the retention with increase of the pH can be observed for 
NFTB and PP due to their acidic properties – NFTB has one hydroxy group, PP 
two, which become more deprotonated and thus more polar and less retained on 
the C18 stationary phase. 
 
 
Figure 20. Chromatograms of NFTB (as mono-ion and dimer) at pH 8.5, 9.0 and 10.0 
using C18 column. Column dead time t0=1.38 min. 
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It can be theorised that, similarly to HFIP and HFTB [25], PP also creates a 
fluorous layer on the C18 stationary phase.  However, the prominent tailing was 
not present for HFIP and HFTB, whereas it is for PP (Figure 21). Once the C18 
stationary phase has been saturated with PP, completely removing it could be 
rather problematic. The observed strong tailing might be related to the structural 
properties of PP, as it has two hydroxy groups (unlike other researched novel 
eluent additives) and possibly due to steric interactions. In contrast, it is 
unlikely that NFTB (Figure 20) creates a fluorous layer on the C18 stationary 
phase due to its weak retention (in comparison to HFIP, HFTB and PP) 
 
 
Figure 21. Chromatograms of perfluoropinacol (as mono-ion and dimer) at the pH 8.5, 
9.0 and 10.0 using the C18 column. Column dead time t0=1.38 min. 
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The retention of TFE on the C18 stationary phase is not very strong as it eluted 
at the beginning (at 2.4 minute, mobile phase pH 9.0) of the chromatographic 
run (Figure 22). Due to the poor ionisation of TFE (Figure 28) in MS, at the 
mobile phase pH 8.5 the peak is not even detected. 
 
 
Figure 22. Chromatograms of the TFE at the pH 8.5, 9.0 and 10.0 using the C18 
column. Column dead time t0=1.38 min. 
 
Changes in the eluent additive retention on the biphenyl stationary phase 
The retention of HFIP and HFTB on the biphenyl stationary phase was not 
strongly influenced by the pH of the mobile phase (Figure 23). HFIP and HFTB 
were also retained far less on the biphenyl stationary phase (with HFTB being 
retained the most at the eluent pH 9.0) – and, unlike with the C18 phase [25], 
both eluent additives eluted from the column under 5 minutes. Thus the 
possibility of a fluorous layer covering the biphenyl stationary phase seems less 
probable than it was in the case of the C18 stationary phase [25]. 
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Similarly to HFIP and HFTB, PP started eluting from the biphenyl column at 
the beginning of the chromatographic run. However, its interaction with the 
biphenyl column is stronger and there is significant tailing (Figure 24), 
especially when the mobile phase pH is 8.5 and 9.0. The decrease in retention 
for novel fluorinated eluent additives with increase of the mobile phase pH ori-
ginates from fluoroalcohols becoming more deprotonated (negatively charged), 
thus less retained. 
 
 
Figure 24. Chromatograms of perfluoropinacol (as mono-ion and dimer) at the pH 8.5, 
9.0 and 10.0 using the biphenyl column. Column dead time t0=0.92 min. 
 
Changes in the eluent additive retention on the PFP stationary phase 
Similarly to the interactions on the biphenyl stationary phase (Figure 23), the 
retention of HFIP and HFTB on the PFP stationary phase was not strongly 
influenced by the pH of the mobile phase (Figure 25). HFIP and HFTB on the 
PFP column likewise did not demonstrate strong retention.  
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PP, similarly to HFIP and HFTB and their interactions with biphenyl and the 
PFP stationary phases, started eluting from the column at the beginning of the 
chromatographic run. Tailing was present also with PFP stationary phase; 
however, only when the mobile phase pH was 8.5 (Figure 26). 
 
 
Figure 26. Chromatograms of perfluoropinacol (as mono-ion and dimer) at the pH 8.5, 
9.0 and 10.0 using the PFP column. Column dead time t0=0.65 min. 
 
Ionisation of the eluent additives 
Similarly to HFIP and HFTB, both NFTB and PP are forming dimers [2M-H]- 
in the MS spectrum (Figure 27). Unlike other additives, TFE was poorly ionised 
(Figure 28). Most pharmaceuticals are basic analytes, thus their detection is 
achieved with positive ionisation mode and at high eluent pH range. The strong 
signals observed for HFIP, HFTB, NFTB and PP in negative ionisation mode 
can hinder detection of analytes, which would also ionise in negative detection 
mode. Based on this, TFE would be suited to use, however it has poor 
chromatographic behaviour. 
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Figure 27. Mass spectra of PP (above) and NFTB (below) at the pH 10.0. 
 
 
 
Figure 28. Mass spectra of TFE at the pH 10.0. 
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4.1.5. Separation of common toxicology screening compounds  
An in-house method for screening (and quantifying) toxicology drugs (Table 9) 
in blood samples consists of a combination of a vast analyte library, as well as 
calibration and QC samples for quantification and verification. The routine 
screening and quantifying method uses both positive and negative ionisation 
modes; however, the vast majority of analytes are detected with the positive 
ionisation mode. The analytical column used is the C18 column for the separa-
tion of the analytes, and the eluent consists of 0.01% formic acid with 5 mM 
ammonium formate, both in the aqueous and organic (MeOH) phase. In order to 
compare the influence of different stationary phases as well as eluent additives 
better, only the columns and eluents are changed, the gradient elution pattern, as 
well as detection, remained the same and more technical information on that can 
be found in the chapter 3.2.5. The dilution for the compound mixture is 
described in the chapter 3.3.2. 
 
 
Table 9. Overview of the detected analytes including aqueous pKa and logP values. 
Constants in italic have been experimentally measured. The rest have been estimated 
with ChemAxon software. [92], [93] 
Analyte pKa1 pKa2 LogP Brief description 
7-Aminoclonazepam 3.03 4.99 0.49 benzodiazepine, metabolite of 
clonazepam 
7-Aminoflunitrazepam 3.32  1.79 benzodiazepine, metabolite of 
flunitrazepam 
Alfentanil 7.50  2.81 potent opioid analgesic 
alpha-Hydroxyalprazolam 4.97 13.72 1.52 benzodiazepine, metabolite of both 
alprazolam and adinazolam 
alpha-Hydroxymidazolam 4.99 13.95 2.48 benzodiazepine, metabolite of 
midazolam 
alpha-Hydroxytriazolam 4.24 13.75 2.04 benzodiazepine, metabolite of 
triazolam  
Alprazolam 5.08  2.37 a short-acting benzodiazepine, 
tradename Xanax 
Amisulpride 7.05  1.06 antipsychotic medication 
Amoxapine 8.83  3.08 tricyclic antidepressant (TCA) 
Aripiprazole 7.60  4.90 antipsychotic medication 
Atenolol 9.60 14.08 0.16 beta blocker, used for cardiovascular 
conditions 
Atropine 9.43 15.15 1.83 belladonna alkaloid, muscarinic 
antagonist (muscle relaxant) 
Benzoylecgonine 9.54 3.15 -0.59 major metabolite of cocaine  
Bisoprolol 9.67 14.09 2.20 medication used to treat heart 
diseases 
Bromazepam 2.68  2.05 benzodiazepine, anti-anxiety 
medication 
Buprenorphine 8.31  4.98 opioid  
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Analyte pKa1 pKa2 LogP Brief description 
Carbamazepine -3.80  2.77 anticonvulsant, analgesic  
Carisoprodol  15.06 2.10 muscle relaxant 
Cetirizine 8.27 2.92 0.86 antihistamine  
Chlordiazepoxide 4.80  2.44 benzodiazepine, sedative  
Chlorpheniramine 9.13  3.38 antihistamine  
Chlorprothixene 9.76  5.18 antipsychotic 
Citalopram 9.78  3.76 antidepressant  
Clomipramine 9.20  5.19 TCA 
Clonazepam 1.86 11.89 2.41 benzodiazepine  
Clozapine 7.50  3.23 antipsychotic medication 
Cocaethylene 8.77  2.60 metabolite of cocaine  
Cocaine 8.61  2.30 strong stimulant, used as a 
recreational drug 
Cotinine 4.79  0.07 alkaloid found in tobacco, 
predominant metabolite of nicotine 
Cyclizine 8.51  3.55 medication to prevent nausea, 
vomiting and dizziness due to motion 
sickness or vertigo 
Desalkylflurazepam 1.80 12.29 3.35 benzodiazepine, active metabolite for 
several benzodiazepines (midazolam, 
flurazepam, quazepam etc)  
Dextromethorphan 9.85  3.49 cough suppressant 
Diazepam 3.40  2.82 benzodiazepine, tradename Valium 
Diclofenac 4.15  4.51 nonsteroidal anti-inflammatory drug 
(NSAID) 
Dihydrocodeine 9.33 14.15 1.55 opioid analgesic 
Diltiazem 8.18 12.86 2.73 medication used to treat high blood 
pressure and certain heart 
arrhythmias 
Diphenhydramine 8.98  3.27 antihistamine, trade name Benadryl  
Dothiepin 9.76  4.52 TCA 
Doxepin 8.96  4.29 antidepressant and anxiolytic 
properties 
Fenazepam 2.89  3.30 benzodiazepine 
Fentanyl 8.99  4.05 powerful synthetic opioid analgesic  
Flumazenil 3.27  1.00 imidazobenzodiazepine derivative 
and a potent benzodiazepine receptor 
antagonist 
Fluoxetine 9.80  4.05 antidepressant, trade name Prozac 
Flupentixol 8.43 15.59 4.51 antipsychotic  
Flurazepam 8.71  3.95 benzodiazepine  
Fluvoxamine 8.86  2.80 antidepressant  
Gabapentin 9.91 3.70 1.25 anti-epileptic medication 
Gliclazide 1.38 4.07 1.73 anti-diabetic medication 
Haloperidol 8.66 13.96 4.30 antipsychotic medication 
Imipramine 9.40  4.80 TCA 
Ketamine 7.50  3.12 potent anaesthetic 
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Analyte pKa1 pKa2 LogP Brief description 
Lamotrigine 5.70  1.93 anticonvulsant for epilepsy and 
bipolar disorder 
Levetiracetam -1.60 16.09 -0.59 epilepsy medication 
Lidocaine 8.01  2.44 anaesthetic  
Lorazepam 1.53  2.39 benzodiazepine 
MDEA   2.50 3,4-methylenedioxy-N-
ethylamphetamine, illegal 
psychoactive drug. 
MDMA 10.14  1.86 hallucinogen, synthetic drug 
Medazepam 9.57  4.21 benzodiazepine  
Methadone 9.20  3.93 potent synthetic analgesic, an opioid 
used for opioid maintenance therapy 
in opioid dependence and for chronic 
pain 
Mianserin 6.92  3.83 tetracyclic antidepressant 
Mirtazapine 7.70  2.90 tetracyclic antidepressant 
M6G 9.12 2.87 -3.00 morphine-6-glucunoride, metabolite 
of morphine  
Naloxone 7.84 10.07 2.09 a medication used to block the effects 
of opioids, tradename Narcan, 
Naproxen  4.15 3.18 NSAID 
Nicotine 8.50  1.17 stimulant and potent 
parasympathomimetic alkaloid 
Nitrazepam 2.61 11.30 2.25 benzodiazepine, hypnotic drug 
Norbuprenorphine 10.49 9.80 3.19 major active metabolite of 
buprenorphine 
Norclozapine 8.83  3.02 major active metabolite of clozapine 
Nordiazepam 2.85  3.21 1,4-benzodiazepine derivative 
Norfentanyl 10.03  1.42 major metabolite of fentanyl 
norsertraline 9.73  4.72 desmethylsertraline, an active 
metabolite of sertraline 
O-Desmethyltramadol 8.97 9.62 2.26 opioid analgesic, the main active 
metabolite of tramadol 
Olanzapine 10.57  4.09 antipsychotic, primarily used to treat 
schizophrenia and bipolar disorder 
Opipramol 7.86 15.59 3.24 anxiolytic and antidepressant 
Oxycodone 8.77 13.57 0.70 opioid, used for the treatment of 
moderate to severe pain 
Oxymorphone 8.17 10.07 0.83 semisynthetic narcotic analgesic 
related  
Paliperidone 8.76 13.74 1.76 antipsychotic medication, also 
primary active metabolite of 
risperidone 
Paroxetine 9.90  2.53 antidepressant  
Phencyclidine 8.29  4.69 drug "angel dust", a hallucinogen 
formerly used as a veterinary 
anesthetic 
Pentazocine 8.80  4.64 opioid 
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Analyte pKa1 pKa2 LogP Brief description 
Pipamperone 8.69  1.87 antipsychotic  
Prazepam 3.06  3.73 benzodiazepine 
Pregabalin 10.23 4.80 -1.30 inhibitory neurotransmitter 
Procyclidine 9.45 13.84 3.79 a muscarinic antagonist, used in the 
treatment of parkinsonism. 
Propoxyphene 9.52  4.18 opioid pain reliever 
Quetiapine 7.06 15.12 2.81 antipsychotic  
Quinine 9.05 13.89 3.44 alkaloid, used to treat malaria and 
babesiosis 
Risperidone 8.76  2.63 antipsychotic 
Ritalinic acid 10.08 3.73 -0.36 α-phenyl-2-piperidine acetic acid, 
inactive major metabolite of 
methylphenidate and ethylphenidate 
Sertraline 9.16  5.51 antidepressant 
Trazodone 6.74  3.13 antidepressant 
Triazolam 4.32  2.42 CNS depressant tranquiliser in the 
triazolobenzodiazepine  
Trimipramine 9.42  4.76 TCA 
Venlafaxine 8.91 14.42 2.74 antidepressant  
Zolpidem 5.65  3.02 sedative, trade name Ambien 
Zopiclone 6.89  0.81 hypnotic agent used in the treatment 
of insomnia 
Zuclopentixol 8.03 15.59 4.22 antipsychotic medication 
Propranolol 9.42 14.09 2.58 hypertension medication 
 
 
4.1.5.1. Experiments with the C18 column and  
DFA as the eluent additive 
Changes in analyte retention  
In order to evaluate the influence of DFA on the mixture of toxicology 
screening compounds, two variations of eluent were compared to the routinely 
used eluent. Firstly, formic acid was replaced with DFA, and the mobile phase 
composition and ionic strength remained the same in the aqueous and organic 
phases. Secondly, to recreate the settings provided in the Waters Application 
note [41] conditions: the 0.15% DFA in the aqueous phase and no additives in 
the organic (MeOH) phase were used. In total, 90 analytes were detected in 
distinct peaks (Table 10). 
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Table 10. A list of detected analytes’ retention factors and peak areas in experiments 
with the C18 column using ammonium formate with formic acid and DFA, and DFA in 
water as eluent additives. 
Analyte 
5 mM Ammonium 
formate and 0.01% 
formic acid pH 4.0 
5 mM Ammonium 
formate and 0.01% 
DFA pH 4.2 
0.15% DFA pH 1.7 
Retention 
factor k 
Peak 
area 
Retention 
factor k 
Peak 
area 
Retention 
factor k Peak area 
7-Aminoclonazepam 9.43 2898111 9.19 3226292 6.32 1213856 
7-Aminoflunitrazepam 10.31 5584733 10.05 5104383 7.31 2050422 
Alfentanil 13.24 4125875 12.98 3998531 11.23 2536162 
alpha-Hydroxyalprazolam 13.60 416346 13.28 858637 12.72 201321 
alpha-Hydroxymidazolam 14.23 2291446 13.91 2996012 10.89 1123637 
alpha-Hydroxytriazolam 13.32 380647 13.00 862205 12.62 389660 
Alprazolam 14.00 3272805 13.68 3510174 13.04 716944 
Amisulpride 7.26 4448202 7.14 4157488 7.19 2298851 
Amoxapine 13.19 2043230 12.89 2719911 11.97 2211673 
Atenolol 5.17 3956536 5.14 4097209 5.35 1899336 
Atropine 7.92 4478535 7.77 4418069 7.85 1536139 
Benzoylecgonine 8.56 5937965 8.35 5901723 8.20 1221250 
Bisoprolol 11.19 5073517 10.92 4667873 10.82 2184952 
Bromazepam 12.79 678413 12.47 1443736 10.74 621045 
Buprenorphine 13.87 2106072 13.64 2545872 11.73 1721386 
Carbamazepine 13.13 3880139 12.80 4210212 12.45 1651171 
Carisoprodol 13.80 634915 13.49 820270 13.12 305707 
Cetirizine 14.52 2817693 14.20 2982567 13.15 760476 
Chlordiazepoxide 14.48 1732148 14.20 2380218 10.22 1185540 
Chlorpheniramine 11.40 6480189 11.12 6246459 8.27 3943451 
Chlorprothixene 14.45 4960057 14.16 4377551 13.73 2331608 
Citalopram 11.74 5438985 11.45 4937412 11.27 2023637 
Clomipramine 14.50 5430649 14.20 4892023 13.80 2487783 
Clonazepam 13.26 213301 12.93 350344 12.52 254690 
Clozapine 12.57 5642586 12.27 5256498 9.18 2674605 
Cocaine 9.21 4777938 9.02 4573040 9.00 3283941 
Cotinine 5.98 4848657 5.87 4577323 4.71 1743976 
Desalkylflurazepam 14.21 737459 13.90 1579661 13.25 954509 
Dextromethorphan 11.82 6548884 11.53 5896432 11.37 2955243 
Diazepam 15.12 4055338 14.81 4043785 13.52 2144827 
Diclofenac 16.10 133121 15.84 246611 15.63 167893 
Dihydrocodeine 5.70 3606878 5.65 3485945 5.87 1168357 
Diltiazem 12.67 5524331 12.38 4903950 12.02 3015642 
Dothiepin 12.90 5887618 12.60 5586179 12.32 3578583 
Doxepin 12.18 6852201 11.88 6425650 11.66 4308421 
Fenazepam 14.73 616854 14.42 1268581 13.96 728745 
Fentanyl 11.41 5672059 11.16 5260491 10.90 3379788 
Flumazenil 11.61 1179185 11.31 1671296 10.87 330774 
Fluoxetine 13.89 2819739 13.60 2614956 13.28 1327125 
Flupentixol 15.55 3723187 15.29 3134092 14.38 1280288 
Flurazepam 11.95 5075711 11.67 4783261 11.37 2729252 
Fluvoxamine 13.76 1432032 13.47 1614421 13.16 731714 
Gabapentin 5.79 596866 5.72 1088017 6.91 354499 
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Analyte 
5 mM Ammonium 
formate and 0.01% 
formic acid pH 4.0 
5 mM Ammonium 
formate and 0.01% 
DFA pH 4.2 
0.15% DFA pH 1.7 
Retention 
factor k 
Peak 
area 
Retention 
factor k 
Peak 
area 
Retention 
factor k Peak area 
Gliclazide 14.44 1260623 14.12 1616483 13.63 500252 
Haloperidol 12.50 4863119 12.21 4386258 11.97 2922277 
Imipramine 13.37 6430744 13.06 6038065 12.76 4051905 
Ketamine 8.71 5484688 8.53 5208540 8.48 3212965 
Lamotrigine 9.61 4522006 9.37 4711889 9.24 2150707 
Lidocaine 8.18 6177367 8.03 5883682 7.96 3864092 
Lorazepam 13.96 190585 13.64 403574 13.29 192197 
M6G 2.17 44229 2.05 46906 3.27 9218 
MDEA 7.82 4673536 7.68 4466032 7.84 2489198 
MDMA 7.16 3640393 7.04 3631693 7.25 1411205 
Medazepam 15.33 7348932 15.03 6859679 11.12 4239890 
Methadone 13.49 7134119 13.19 6720527 12.90 5374065 
Mianserin 12.19 5346787 11.90 4708806 11.39 1630936 
Mirtazapine 10.13 6359476 9.91 5990665 6.86 2037238 
Naloxone 6.67 2046617 6.58 2221185 6.68 914145 
Nicotine 1.56 2286200 1.59 2408091 0.27 2355572 
Nitrazepam 13.30 251755 12.95 521185 11.65 599627 
Norbuprenorphine 11.19 417167 10.93 662643 10.81 424529 
Norclozapine 12.52 3365070 12.22 3650665 8.77 2301619 
Nordiazepam 14.82 1576423 14.51 3452460 12.40 2666949 
Norfentanyl 8.78 4393091 8.59 4525236 8.67 2117357 
Norsertraline 14.55 23227 14.26 20478 13.83 23279 
O-Desmethyltramadol 7.21 4899159 7.09 4945684 7.24 3087007 
Olanzapine 9.59 5170484 9.40 3884694 6.83 1551837 
Opipramol 13.30 4899212 13.00 4664611 11.42 2520311 
Oxycodone 6.16 2414654 6.08 2465491 6.25 910652 
Oxymorphone 3.42 953072 3.52 1356655 3.88 702579 
Paliperidone 10.24 3175865 10.01 2872411 9.52 1559899 
Paroxetine 13.10 1586154 12.80 1726109 12.52 960584 
Pentazocine 10.57 6547758 10.33 6075655 10.23 3955781 
Phencyclidine  10.90 4146554 10.65 3873744 10.56 3371744 
Pipamperone 11.26 4441772 11.00 4104455 7.11 2106017 
Prazepam 16.24 3722100 16.00 3795695 15.41 1932855 
Pregabalin 3.94 272905 5.76 582639 6.77 221855 
Procyclidine 13.21 7321863 12.91 6986987 12.64 5651227 
Propranolol 11.66 5150872 11.37 5151344 11.20 2904844 
Quetiapine 12.82 5890978 12.53 5319024 10.15 2939052 
Quinine 10.55 4352073 10.30 4197781 6.98 1439155 
Risperidone 10.98 4558812 10.73 4025677 9.19 2453862 
Ritalinic acid 8.59 1061092 8.37 2024201 8.37 616767 
Sertraline 14.31 1890917 14.02 1813934 13.64 741367 
Trazodone 11.57 5132553 11.30 4537790 10.21 2470427 
Triazolam 13.90 2445262 13.59 2632013 13.19 1096095 
Trimipramine 13.80 7007815 13.51 6675749 13.15 4688637 
Venlafaxine 11.25 6865708 10.97 6485294 10.85 4870681 
Zolpidem 10.93 6105804 10.69 5833387 9.62 4265537 
Zopiclone 9.21 927412 8.98 1046577 8.67 204155 
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Roughly a half of the analytes studied (42 analytes out of 90, Table 10) showed 
a consistent decrease in retention factors when the 0.01% formic acid was 
replaced with the 0.01% DFA and an even further decrease in retention with an 
increase in concentration to the 0.15% DFA. Most of these analytes were 
benzodiazepines. Analytes with a difference in retention times higher than 1.5 
minutes can be seen in Figure 29. Three analytes which had the largest decrease 
were chlordiazepoxide pKa 4.8, logP 2.44, medazepam pKa 9.57, logP 4.21 and 
pipamperone pKa 8.69, logP 1.87. The pKa values or LogP do not explain why 
there is such a large change in the case of exactly these three analytes. 
 
 
 
 
Figure 29. Retention factors of 11 analytes when the 0.01% formic acid with 5 mM 
ammonium formate and the 0.01% DFA with 5 mM ammonium formate and the 0.15% 
DFA were used as eluent additives. 
 
 
The other large part of the analytes (44, Table 10) had little to no change in 
retention when DFA was used as the eluent additive. However, even then, the 
vast majority (34 analytes out of 44) showed a small (not larger than 0.3 units) 
decrease in the retention factors when formic acid was replaced with DFA and 
then a larger (but not exceeding change of 0.5 units) decrease when the DFA 
concentration was increased and ammonium formate was not present in the 
eluent. Because all analysed drugs have either basic functional groups or both 
basic and acidic functional groups with an increased acidity (the pH of the 
0.01% formic acid solution was 4.0, the pH for the 0.01% DFA solution was 
4.2, and for the 0.15% DFA the pH was 1.7) of the eluent, basic analytes 
become more protonated, thus more polar and thus they elute faster. 
Only a small group – four analytes (Figure 30) – showed different relation-
ships either an increase in retention when formic acid was replaced with DFA in 
0.0
4.0
8.0
12.0
16.0
Retention
factor
k
0.01% Formic Acid 0.01% DFA 0.15% DFA
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the mobile phase (for analyte pregabalin) or an increase when the 0.15% DFA 
was used – the analytes gabapentin and M6G (morphine-6-gluconiride, one of 
the morphine metabolites). The only analyte showing a notable decrease in 
retention only when the 0.15% DFA was used (but not for the 0.01% DFA), was 
nicotine. All four analytes have pKa values either between 8.5 and 10.23, which 
means the majority of basic functional groups are present in the protonated BH+ 
form. Pregabalin also has the carboxylic acid (-COOH) functional group (with 
pKa 4.8), which means that with a decrease in the pH, the acidic group shifts 
equilibria from A- towards AH, becoming less polar and more retained on the 
C18 stationary phase – which can be seen as an increase in retention time. 
Similarly, M6G has glucuronic acid in its structure, which is why an increase in 
retention can be seen with the 0.15% DFA as the eluent.  
 
  
Figure 30. Retention factors of four analytes when the 0.01% formic acid with 5 mM 
ammonium formate and the 0.01% DFA with 5 mM ammonium formate and the 0.15% 
DFA were used as eluent additives. 
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Changes in analyte ionisation 
For 48 analytes the highest MS signal was obtained when the routine eluent (the 
0.01% formic acid with 5mM ammonium formate both in the aqueous and 
organic phases) was used. For 40 analytes, the highest signal MS signal was 
obtained when the 0.01% formic acid in routine eluent was replaced with the 
0.01% DFA. However, the difference in peak areas between mobile phase 
containing 0.01% of formic acid or 0.01% DFA was insignificant (changes  
in retention were evident only by 1–1.5 times). Only five analytes:  
alpha-hydroxyalprazolam, bromazepam, gabapentin, ritalinic acid and 
pregabalin had larger increase in the signal (by 1.8–2.4 times), when the 0.01% 
DFA was used as the eluent additive instead of the 0.01% formic acid.  
The eluent, which consisted of the 0.15% DFA and MeOH, consistently 
gave the lowest MS signal (on average by 2.3 times) for the majority (78) of the 
detected analytes when compared to eluent compositions containing 0.01% 
formic acid or 0.01% DFA.  
Only for two analytes (nitrazepam and norsertraline) the MS signal was the 
highest when the 0.15% DFA was in use. For nitrazepam increase in signal 
when DFA was used was by 2.1–2.5 times, but for analyte norsertraline peak 
areas were overall small and differed only 1.002–1.1 times. 
 
 
4.1.5.2. Experiments with biphenyl column and  
HFTB as eluent additive 
Changes in analyte retention  
In total 81 analytes were detected as distinct peaks (Table 11), when using the 
biphenyl column and two eluent additives: ammonium acetate and HFTB, both 
at the pH values 8.5 and 9.0. Slightly less than a half of the analytes (33) were 
not influenced (or were influenced minimally) by the change of the eluent 
additive or pH value. 26 out of the 33 of not influenced analytes had low (less 
than 8) pKa values, meaning that at a high pH, they are predominantly in the 
non-protonated form (B) and therefore not largely influenced by changes of the 
pH or eluent additive. 
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Analytes which were retained less on the biphenyl column when HFTB was 
used as the eluent additive (Figure 31) also had low pKa values (between  
1.38–4.15, Figure 32), except for cetirizine (an antihistamine) and M6G, which 
have pKa values of 8.27 and 9.12, respectively. However, these analytes also 
have carboxylic and glucuronic acid groups in the molecules’ structure, which 
are deprotonated at a high pH. HFTB as an ion-pairing reagent presents 
competition to acidic deprotonated (polar) analytes in the column. Thus, it is 
also possible to see shorter retention times as well as repulsive forces between 
the anion and π-systems. 
There were three analytes, which had carboxylic group in their structure, 
however, their retention did not decrease when HFTB was used (ritalinic acid, 
pregabalin and benzoylecgonine). These three analytes also have high pKa 
values (9.54–10.23), meaning they are protonated at used mobile phase pH. 
 
  
Figure 31. Retention time of six analytes when using ammonium acetate and HFTB as 
the eluent additives using biphenyl column at the pH values of 8.5 and 9.0. 
 
 
There were 26 analytes which presented a clear increase in retention factors 
when HFTB was used as the eluent additive. All of them had high pKa values 
(group “increase” in Figure 32) – in pKa the interval was 7.5–10.14. The analy-
tes which had stronger retention also had higher logP values when compared to 
those of the rest of the detected analytes. Only one analyte – oxymorphone had 
a logP value less than 1. All of that combined makes an analyte less polar, and 
therefore it elutes late when the organic phase (MeOH) content is higher. 
Likewise, 16 analytes which displayed a change in the retention factors 
when the eluent additives and the pH values changed also had higher pKa values 
(Figure 32). However, no clear pattern was observed. Largest part, 33 analytes 
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in total, demonstrated no change in retention times (group “no change in reten-
tion” in Figure 32) 
 
 
 
Figure 32. Box plots for the pKa values of the analytes, which are grouped into four 
categories according to the observed relationship of the retention factors, eluent additive 
and pH. Analytes with either observed an increase or no clear relationship had higher 
pKa values with a narrower range. Analytes, which saw either a decrease or no change in 
retention had a wide range of pKa values. However, the majority of them had lower pKa 
values. 
 
 
Changes in analyte ionisation 
Both an increase and decrease in the MS signal were observed between diffe-
rent eluent additives and pH values. All signal values were compared to those 
obtained when ammonium acetate, the pH 8.5, was used as the eluent additive: 
• when ammonium acetate was used at the pH 9.0, 41 analytes had a 
decrease in the signal, 30 analytes had a signal increase in the range of  
1–2 times and 10 analytes saw a more than two-fold signal increase. The 
biggest increase in signal intensity, 10.8 times, was observed for the 
analyte bisoprolol; 
• when HFTB was used at the pH 8.5, 26 analytes saw a decrease in the 
signal, 30 analytes saw a signal increase in the range of 1–2 times and 25 
analytes saw a more than two-fold signal increase. The biggest increase 
in signal intensity, 8.5 times, was observed for the analyte procyclidine; 
• when HFTB was used at the pH 9.0, 25 analytes had a decrease in the 
signal, 25 analytes saw a signal increase in range of 1–2 times and 31 
analytes saw a more than two-fold signal increase. The biggest increase 
in signal intensity, 10.1 times, was observed for the analyte procyclidine. 
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Thus, while there is little difference between the ammonium acetate eluent at 
the pH values 8.5 and 9 (roughly a half of the analytes saw an increase and the 
other half – a decrease), there is mostly a significant signal improvement when 
HFTB is used as the eluent additive, especially at the pH 9.0 – when 31 analytes 
experienced a signal that was at least two times larger. Seven analytes: atenolol, 
bispropol, dextromethorphan, doxepine, procyclidine, imipramine and ketamine 
demonstrated an increase in signal intensity by 5–10 times. 
The majority of signal improvement when HFTB was used as the eluent 
additive was for the analytes which had either consistent retention times or saw 
a decrease in retention times when HFTB was used as the eluent additive. A 
possible explanation for that is if analytes eluted faster from the column, the 
amount of the aqueous phase % was larger and thus, also the concentration of 
HFTB, which has proven to help with signal enhancement.  
 
 
4.1.5.3. Experiments with the PFP column and  
HFTB as the eluent additive 
Experiments performed with the PFP column comparing results obtained when 
the routine eluent (the 0.01% formic acid 5mM ammonium formate both in the 
aqueous and organic phases) were compared to those obtained when the eluent 
used had 5mM HFTB as the eluent additive, at the pH values: 8.5 and 9.0. The 
change in a previously used reference buffer for the biphenyl column (5mM 
ammonium acetate, the pH 8.5 and 9.0) was made to obtain a better comparison 
between the in-house method and change in the retention and ionisation when 
the PFP column was used. Altogether, data were recorded for 42 analytes as 
distinct peaks (Table 12) – other analytes either retained too poorly or too 
strongly on the PFPF stationary phase. Generally, observed retention patterns 
fell into three groups:  
1. for 14 analytes little to no change in retention factors was observed  
2. for 14 analytes an increase when HFTB was used as the eluent additive 
was observed, with the largest retention factors recorded when the eluent 
pH was 8.5  
3. for 9 analytes the retention factors were the largest when the routine 
eluent was used.  
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Table 12. A list of the detected analytes’ retention factors and peak areas in experi-
ments with the PFP column using ammonium acetate and HFTB as the eluent additives. 
Analyte 
5 mM Ammonium 
formate and 0.01% 
formic acid pH 4.0 
HFTB pH 8.5 HFTB pH 9.0 
Retention 
factor k Peak area
Retention 
factor k 
Peak 
area 
Retention 
factor k 
Peak 
area 
Alfentanil 14.69 10790304 14.78 3933509 14.71 2836261 
Alprazolam 13.91 7043462 13.91 908388 13.87 1052439 
Aripiprazole 17.36 8194655 17.58 1558059 17.37 929312 
Bisoprolol 13.73 13297416 22.98 2923078 18.78 2131095 
Carbamazepine 11.65 7472914 11.64 1227111 11.62 895109 
Cetirizine 13.90 9190298 11.92 1595905 11.26 1090408 
Clonazepam 12.80 948621 12.70 133499 12.63 78442 
7-Aminoclonazepam 9.40 11193642 9.24 780776 9.25 441199 
Clozapine 14.71 9568414 16.70 1754431 16.44 1052899 
Cocaethylene 13.84 163881 19.42 122807 18.73 72455 
Cocaine 12.66 11982865 18.51 7278681 17.85 4586762 
Benzoylecgonine 10.62 5853895 9.64 637814 9.59 604409 
Cyclizine 14.73 6885393 18.03 2364137 17.54 1415069 
Diazepam 14.22 9766308 14.24 1021489 14.21 832108 
Diclofenac 14.30 609696 4.12 47208 4.12 5545 
Dihydrocodeine 8.32 7972539 18.94 2294721 18.42 1755607 
Diltiazem 15.50 13965430 16.86 5240261 16.55 3574891 
Fentanyl 15.15 1286859 17.28 561681 16.83 341064 
Norfentanyl 10.93 4329364 22.27 1981760 19.01 998341 
7-Aminoflunitrazepam 10.81 11265844 10.71 1822722 10.66 1365965 
Gabapentin 5.21 2524287 2.93 497166 2.84 291184 
Gliclazide 13.57 2592383 4.34 200272 4.65 179890 
Ketamine 11.11 7871376 13.87 1985194 13.46 1234050 
Lamotrigine 10.89 26715395 9.30 2977406 9.21 2655654 
Levetiracetam 5.12 2889124 5.23 159410 5.09 19192 
Lidocaine 10.63 9441405 15.10 3073209 14.82 1618922 
Lorazepam 12.35 869623 12.34 102072 12.34 100088 
Mirtazapine 12.63 10706870 16.53 2641459 16.32 2021736 
Naproxen 13.82 588068 1.68 37807 1.97 16721 
Nitrazepam 12.78 1155330 12.65 215367 12.58 136624 
Nordiazepam 13.37 3020351 13.37 623960 13.35 551707 
Oxycodone 8.90 5328067 17.10 969006 16.22 534135 
Paliperidone 13.59 10809380 17.01 4114550 16.20 2709541 
Pregabalin 5.84 1491399 2.55 230995 2.44 222991 
Procyclidine 15.41 13426668 21.62 8136229 18.33 4187546 
Quetiapine 14.64 12702296 14.93 3234697 14.71 1901231 
Quinine 14.61 8926433 19.06 3038643 18.46 1769459 
Risperidone 14.97 12592250 17.75 6929731 17.27 3845949 
Trazodone 14.58 11658604 15.47 3236148 15.35 2661362 
Zolpidem 14.01 16871378 14.30 6562196 14.22 4093063 
Zopiclone 11.72 3057176 14.06 175172 13.93 200131 
Zuclopentixol 18.46 1147058 18.26 601426 17.78 255559 
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The majority of analytes with the constant retention times also had low pKa 
values (below 7.6, group “no change in retention” in Figure 33). Also, addition 
of organic solvent (MeOH) lowers the pKa values of basic analytes [17]. If the 
basic analyte’s pKa value is below that of eluent’s pH, the majority of the basic 
functional groups in the analytes are presented in the deprotonated B form. As 
neutral analytes, these did not interact with HFTB and are not influenced by the 
change of a high pH.  
 
 
 
Figure 33. Box plots for pKa values of the analytes, which are grouped into three 
categories according to the observed relationship between the retention factors and 
eluent additive as well as the pH of the aqueous phase. 
 
Analytes which demonstrated an increase in retention time when the novel 
eluent additive HFTB was used, especially at the pH 8.5 (Figure 34), all had 
relatively high pKa values – in the range between 6.7 and 9.7 (Figure 33), which 
means the basic groups in analytes are influenced by the change in the used pH 
range of 8.5 and 9.0. 
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Figure 34. The retention time of 15 analytes when using the 0.01% formic acid with 
5mM ammonium acetate at pH 4.0 and HFTB as eluent additives at the pH values of 8.5 
and 9.0. 
 
 
The nine analytes, which were less retained on the PFP column when HFTB 
was used as the eluent additive, have the largest variation (Figure 33) of pKa 
values. However, these are the only six detected analytes (benzoylecgonine, 
cetirizine, diclofenac, gabapentin, naproxen and pregabalin) that have the 
carboxylic (-COOH) group in their structure. Out of the other two analytes, one 
has a hydroxy group (zuclopentixol), one an -SO2 group (gliclazide). The last 
analyte in the group, which does not have a carboxylic group, is lamotrigine. At 
a high pH, the carboxylic group would be present in the polar deprotonated (A-) 
form, while the basic functional groups would be in equilibria between the polar 
(BH+) and deprotonated B forms (depending on the pKa values), but with the 
protonated form in the majority. HFTB has additional ion-pairing properties, 
however it can still form ion-pairs with protonated basic analytes in the mobile 
phase. It is possible that due to deprotonated acidic functional group, these pairs 
are not formed.  
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Figure 35. Retention time of 9 analytes when using 0.01% formic acid with 5mM 
ammonium acetate and HFTB as eluent additives at pH values of 8.5 and 9.0. 
 
 
Changes in ionisation 
For all analytes, the undoubtedly best signal intensity was obtained using the 
routine eluent system, at times giving even a 100-fold increase when compared 
to the MS signal obtained when HFTB was used. Between the HFTB pH 8.5 
and 9.0, on average the signal obtained at the pH 8.5 was 1.6 times higher than 
that obtained at the pH 9.0. Few exceptions were observed: three cases – 
alprazolam, lorazepam and zopiclone – when a better signal was obtained at the 
pH 9.0, and two cases – diclofenac and levetiracetam – which saw an increase 
in signal intensity by 6.8 and 8.5, respectively, when the HFTB 8.5 was used as 
an aqueous phase. 
 
4.2. Practical applications 
In order to research the possible influence of novel eluent additives in real-life 
applications, two bioanalytical methods with the aim to obtain data usable in 
PK/PD studies were developed and fully validated according to the European 
Medicines Agency (EMA) guideline [49]. The main reason for using novel 
eluent additives was that these methods were aimed to achieve incredibly low 
lower limits of quantification (LLOQ) of the pharmaceutical compounds in a 
very small volume of the sample. The need for low concentrations and sample 
volumes arose from the larger clinical study design, as the population consisted 
of paediatric patients and neonates. 
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4.2.1. Challenges of the data below the analytical limit of 
quantitation in pharmacokinetic analysis [II] 
When developing a bioanalytical method, it is important to choose calibration 
range fit for the purpose of the study. For quantification of well-known pharma-
ceuticals there is information available, which describes the usually encountered 
concentration ranges in blood plasma in humans. Those are called the thera-
peutic drug ranges and they describe how much of analyte is needed to achieve 
the therapeutic effect. However, the situation becomes considerably more 
complex in case of PK/PD studies, where sometimes only an inkling of possible 
ranges is available and furthermore, when PK/PD study sampling population is 
paediatric patients (meaning analyte concentration can be very low). Addition 
instrumentation that lacks good sensitivity increase the risk of choosing too high 
LLOQ values. This can lead to significant amount of measured samples pro-
ducing results that fall below LLOQ values. 
Due to the rules set by different bioanalytical method validation guidelines 
[94]–[97], the data which are obtained during the quantification of an analyte 
using a bioanalytical method, but falls below the limit of quantification, cannot 
be released as it lacks the required precision evaluation. Usually, these data 
points are simply marked as BLQ. However, the inclusion of the data can 
contribute to a smaller imprecision and bias in model-based PK analyses [65]. 
Additionally, since no numerical value is provided, a statistical treatment for 
BLQ data points must be used. The most common methods of this include the 
exclusion of BLQ data, partial exclusion, or substitution with the halved value 
of LLOQ, the actual value of LLOQ or zero.  
It is important to note that there always can be data that fall below the limits 
of quantification. If that happens, the best way to deal with BLQ data would be 
to minimise the impact of its occurrence but in order to achieve that, there has 
to be cooperation between PK modellers and bioanalytical scientists. This 
would improve study protocols by ensuring the most suited and needed con-
centration ranges and that assay sensitivity parameters are met. If there are 
many BLQ data points in an assay, a re-assessment of the assay should be done 
and the LLOQ should be lowered, which is both a time- and resource 
consuming process and should be avoided.  
Likewise, an introduction of a harmonised limit of detection (LoD) defini-
tion in the validation guidelines, which is not dependant on the signal to noise 
ratio, should be encouraged. From the already acquired data, the LoD can be 
calculated using formula (2): 
 
𝐿𝑜𝐷 = 3.3 ∗  ௌ஽(௅௅ைொ)ௌ  (2) 
 
SD(LLOQ) in the formula marks the standard deviation of the analyte response 
measured from the replicate measurements in the LLOQ sample (or the analyte 
and internal standard response ratio). S stands for the slope of a line drawn 
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between the origin and the mean response of the replicates at the nominal 
LLOQ concentration. 
Using the formula (2), LoD estimations are quite conservative. There are 
alternative LoD estimation techniques [98], [99], which lead to more statis-
tically accurate LoD value due to less assumptions made, however they require 
additional experiments, which are not included in the validation guidelines. 
Still, using the LoD should be encouraged as it can both demonstrate analytical 
performance and give data analysts the chance to make the final decision about 
the inclusion or exclusion of BLQ data in a model.  
 
 
 4.2.2. Method development and validation for the analysis of 
morphine, clonidine and midazolam and their metabolites [I]  
All six analgesic analytes (morphine, it’s two metabolites M3G and M6G, 
clonidine, midazolam and its metabolite MiOH) in the CLON01 ("Clonidine for 
Sedation of Paediatric Patients in the Intensive Care Unit) study have basic 
properties, as shown by their pKa values (Table 13). 
The eluent’s aqueous phase was chosen to fit those basic analytes’ require-
ments – 5mM HFIP and the pH was adjusted to 9 (with ammonium hydroxide), 
as HFIP is a weak acid (pKa 9.3 [19]). A chromatogram obtained under these 
conditions can be seen in Figure 36.   
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In order to simultaneously detect morphine as well as its two metabolites, they 
all had to be chromatographically separated. The reason for this is that both 
M3G and M6G undergo in-source collision induced dissociation (CID) that 
results in the loss of the glucuronic acid component. Without it, the fragment 
m/z remaining is identical to that of morphine (m/z 286). If the three analytes  
are not chromatographically separated, glucuronides would contribute to the 
morphine signal [78].  
As a novel fluorinated eluent additive, the HFIP in the basic mobile phase 
acts as a weak ion-pairing additive. Due to the glucuronic acid group with pKa2 
2.87, at the used eluent pH it is completely deprotonated, thus making analytes 
polar and not well retained on the RP column. Furthermore, as seen by results 
described in 4.1.5.3, an acid group in the molecule decreases the retention of the 
analyte if a novel fluorinated eluent additive is used. As a result, both M3G and 
M6G elute early during the chromatographic run (Figure 36), even if their basic 
group has the highest pKa value of the studied analytes (Figure 37). Clonidine 
and morphine have similar pKa values; however, morphine is less lipophilic 
based on their logP values; thus it elutes faster. Both MiOH and midazolam 
should be in a completely protonated form in the aqueous solution; however, 
midazolam is more lipophilic. It also elutes when the MeOH content is 100% 
(Figure 37). 
The use of HFIP as a novel eluent additive also helped to reach the needed 
lowest limits of quantification (50 pg/mL) by increasing instrument sensitivity.  
The developed and validated (according to the EMA guideline [49]) method 
has been successfully applied to samples collected under the CLON01 
(“Clonidine for Sedation of Paediatric Patients in the Intensive Care Unit”) 
study. The CLON01 study was a randomised, double-blind controlled clinical 
trial, funded by the European Commission Seventh Framework Programme 
with the aim to compare the use of clonidine with midazolam in paediatric and 
neonatal ICUs. In addition to clonidine or midazolam, patients also received an 
analgesic component – morphine. The goal of the study was to analyse PK for 
all three drugs and to develop dosage guidelines for sedation in ICUs for 
paediatric and neonatal patients. 
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Figure 37. Gradient composition over time with corresponding analytes’ pKa values in 
the order of analyte elution – M3G, M6G, morphine, clonidine, MiOH and midazolam. 
 
 
4.2.3. Method development and validation for analysis of 
milrinone and dobutamine [III, V, VI] 
 
Analysis of milrinone and dobutamine 
A very sensitive and selective method for the simultaneous determination of 
milrinone and dobutamine (Figure 38) was developed and validated for simulta-
neous measurement in neonatal plasma samples, using only a sample volume of 
20 µL (the lowest known reported). To reach the needed sensitivity with the 
minimal amount of sample, NH4F was used as an eluent additive. While it is not 
uncommon to see a positive influence on the signal of NH4F in the negative ion 
mode, the same cannot be said about the positive ion mode. A comparison of 
different eluent compositions (the 0.1% formic acid versus NH4F) showed a 
signal increase for both analytes. For milrinone, the signal increased two times, 
but for dobutamine – seven. 
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Results from clinical studies 
The method was developed and validated according to the EMA guideline [49], 
and successfully applied to measuring samples from a two-centre study in 
Estonia (Tallinn Children's Hospital and Tartu University Hospital): no. 2015-
004836‐36 (the registered number in the EU Clinical Trials Register). The 
obtained results were further used to describe the PK of milrinone and 
dobutamine in neonates in papers [V] and [VI]. 
 
Ionisation of model analytes when using NH4F with the biphenyl column 
In order to test the influence on ionisation and dependence on either pKa or logP 
values in the positive ion detection mode, the peak areas of the analytes were 
compared between using ammonium acetate and the NH4F eluent at the pH 8.5 
with the model analytes from Table 5. However, the results were inconclusive 
mainly due to the fact that peak areas varied greatly between injections, which 
led to large standard deviations (Figure 39). 
 
 
 
Figure 39. Comparison between peak areas for basic polar analytes group BH+ and 
milrinone and dobutamine when ammonium acetate and NH4F was used as eluent 
additives at pH 8.5. 
While both milrinone and dobutamine saw increase (2 times for milrinone and 
1.3 for dobutamine), when NH4F was used as eluent additive at pH 8.5, the 
increase or decrease remained analyte specific and there was no relationship 
between analytes logP and pKa values. Thus it can be seen while NH4F 
increased signal for some analytes, the enhancement was not as significant as it 
was seen for acidic conditions.  
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SUMMARY 
This work aimed to expand different novel eluent additives for use mainly in 
HPLC-MS systems. Another aim was to further research the retention mecha-
nisms on reversed-phase columns and any influence had on the analyte 
ionisation on MS detection when different eluent additives at a predominantly 
high mobile phase pH were used. 
As eluent additives, three fluoroalcohols (HFIP, HFTB and PP) are well 
retained on the C18 stationary phase, therefore it can be theorised that they 
create an anionic fluorous layer, which is very attractive for basic polar 
analytes, but repels acidic polar analytes. NFTB is not well retained; however, 
due to its low pKa value it is completely deprotonated at a high pH and can still 
create ion-pairs with basic protonated analytes in the mobile phase. As for 
biphenyl and the PFP stationary phases – HFIP, HFTB are not retained on these 
stationary phases and thus most likely do not create the fluorous layer. PP is the 
only additive which presented a long tailing (even if it eluted quickly) and thus 
could possibly create a fluorous layer also on the biphenyl stationary phase.  
Thus, for retention on the C18 stationary phase there is a possibility of dual 
interaction – between the analyte and fluorous layer created by the fluorinated 
eluent additive and the interaction of the eluent additive with the analyte in the 
mobile phase. For common eluent additives (ammonium acetate, bicarbonate 
and formate), change in retention is only due to the change in equilibria 
between the analyte’s polar (A- or BH+) and non-polar (AH and B) forms. This 
is especially well demonstrated for polar basic analytes – when a sharp increase 
in all analytes’ retention from the pH 8.5 and 9.0 to the pH 10.0 was observed. 
Since there is little to no change between the ionised and non-ionised forms of 
an analyte due to their pKa values, then for the two neutral analyte groups 
retention changed very little, as they are not influenced by the change of the 
mobile phase pH.  
While the changes in retention when novel eluent additives are used to large 
extent follow the same patterns already observed with conventional eluent 
additives, as they are also dependent on the equilibria between polar and non-
polar analyte form, these changes are amplified. For non-polar analytes, the 
retention factors varied more, and as most of the AH group analytes have pKa 
values around 10 and thus are partly protonated at a higher eluent pH, the 
retention was overall smaller when HFIP and HFTB were used. In general for 
acidic analytes, smaller retention factors (on top of the decrease in retention 
with the increase of the mobile phase pH) were observed when compared to 
conventional eluent additives. This is due to the fact that acidic polar analytes 
not only have to compete for a place on the stationary phase, but they are also 
additionally repelled by the deprotonated HFIP, HFTB, NFTB and PP eluent 
additives. Due to the pKa values of HFIP, HFTB and PP with increase of the 
eluent pH, also these novel eluent additives become more deprotonated and 
increasingly repelling to acidic analytes. For basic neutral analytes, a simply 
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larger variation in retention factors was present, without a clear increase or 
decrease. However, the largest influence of novel eluent additives was un-
doubtedly observed for basic polar analytes. The increase in retention with the 
increase of the pH eluent observed when HFIP and HFTB were used was more 
gradual than when conventional eluent additives were used and with overall 
larger retention factors. For some analytes, the retention increased 28 and 35 
times when using novel eluent additives. For one basic protonated analyte 
fluoroalcohol PP increased the retention factor by 41 times. PP is especially 
promising due to its structural properties – two hydroxy groups, which means 
PP also has two pKa values. Thus PP has good potential to be used as an ion-
pairing reagent also in the case of the low mobile phase pH values. NFTB 
showed the same influence patterns on basic analytes as other novel eluent 
additives. 
As for TFE and DMSO – due to their minimal buffering capacity, it was 
impossible to achieve the stable mobile phase pH 8.5 and 9.0. Likewise, 
considerably lower analyte signal was observed – either due to suppression or 
non-optimal source parameters in case of DMSO. Thus, both are deemed not to 
be suitable for further use in bioanalytical methods. 
Overall, the retention of analytes on the biphenyl stationary phase was 
greater due to the π-π interactions, but there were some exceptions – all analytes 
containing a nitro group were very poorly retained, even if they had a benzene 
ring in their structure. Furthermore, both neutral analyte groups – the protonated 
acidic analytes and deprotonated basic analytes – were more influenced by 
changes in the pH of the mobile phase than when the C18 column was used. 
The largest difference in retention between the C18 and biphenyl stationary 
phases for acidic analytes was observed at the eluent pH 8.5 – when a smaller 
part of the analyte is deprotonated and thus due to the additional π-π or halogen-
π interactions, the analyte is better retained on the biphenyl column. For basic 
polar analytes, even without clear π-π interactions (as none of the BH+ group 
analytes had an aromatic ring in its structure), the retention was stronger than 
that seen with the C18 column. A higher logP value also ensured better 
retention for polar basic analytes. 
In order to expand this research into the practical field, the separation of a 
large set of common toxicology analytes (all with at least one basic functional 
group) was studied. An in-house method for screening with gradient elution 
(thus influence of pH was decreased) was used as a comparison to novel eluent 
additives. Firstly, the influence of DFA was tested in comparison with the in-
house method on the C18 stationary phase column. While the change from 
formic acid to DFA in the in-house buffer (where also ammonium formate is 
added) did not make a significant difference in retention or ionisation, using the 
eluent only with DFA did. 42 analytes out of 90 showed a significant decrease 
in retention, mainly due to a decrease in the eluent’s pH. The increase of 
retention when DFA was used could be seen for analytes with acidic functional 
groups in their structures. As for analyte ionisation, DFA gave a consistently 
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lower signal if compared with the obtained peak areas when formic acid was 
used. 
The change to a different stationary phase (biphenyl) demonstrated a decrease 
in number of the analytes detected. A half of the analytes were not influenced by 
the change of the eluent additives (ammonium acetate and HFTB), nor were 
they affected by a change in the pH from 8.5 to 9.0. Analytes which demon-
strated a decrease in retention when HFTB was used as the eluent additive had 
either low pKa values or a carboxylic functional group in their structure. 
Analytes which showed an increase in retention when HFTB was used as the 
eluent additive also had higher pKa as well as higher logP values, meaning a 
larger part of the basic analyte was in the polar form and thus interacting more 
readily with HFTB by forming ion-pairs with the fluoroalcohol. When HFTB 
was used as the eluent additive, the majority of analytes showed an increase in 
the MS signal, especially when the eluent’s pH was 9.0. 
The biggest difference in retention was presented when the PFP column was 
used as only 42 analytes were recorded as distinct peaks – other analytes either 
retained too poorly or too strongly on the PFP stationary phase, even if the in-
house acidic mobile phase conditions were used. Analytes with pKa values 
below 7.6 saw no change in retention when HFTB was used as the eluent 
additive. Again, analytes which were retained less when HFTB was used, also 
had a carboxylic acid functional group in their structure. Just like with the 
biphenyl column, the acidic functional group, which is deprotonated at the used 
high eluent pH, demonstrated that ionic interaction between the negatively 
charged functional group in the analyte and the likewise deprotonated novel 
fluorinated eluent additive is more important in terms of influence on retention 
than the attraction of the protonated basic functional group. 
In this doctoral dissertation, two practical applications were presented: 
method development and validation for pharmaceutical analytes with the aim to 
obtain data usable for PK/PD studies. Both methods were fully validated 
according to the EMA guideline and reached incredibly low limits of quanti-
fication with a minimal sample amount used. One method was created to 
quantify three sedative drugs – morphine, clonidine and midazolam with their 
metabolites M3G, M6G and MiOH. Using HFIP as the eluent additive enabled 
the separation of M3G and M6G and morphine analytes, which have the same 
fragmentation patterns. The other method, which focused on the cardiovascular 
drugs milrinone and dobutamine, demonstrated an increase in the signal: two 
times for milrinone and seven times for dobutamine when NH4F was used as the 
eluent additive. An increase in the signal observed ensured less data being 
marked as BLQ, which cannot be realised due to the guidelines and has a 
detrimental influence on PK/PD modelling. Further research on the NH4F 
influence on analyte ionisation in the positive detection mode was done; 
however, the results remained very analyte dependant. 
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SUMMARY IN ESTONIAN 
Uudsed eluendilisandid LC-MS baasil  
bioanalüütilistele metoodikatele 
Käesoleva töö eesmärk oli laiendada teadmisi uudsete eluendilisandite kasuta-
mise kohta peamiselt kõrgrõhu vedelikkromatograafia-massispektromeetria 
(HPLC-MS) meetodites. Lisaks uuriti põhjalikumalt retentsioonimehhanisme 
kasutades erinevate pöördfaaskromatograafilisi statsionaarseid faase ja lisandite 
mõju analüütide ionisatsioonile nende määramisel massispektromeetriga. Lisan-
deid kasutati peamiselt kõrgete mobiilfaasi pH’de juures. 
Uuritud eluendilisanditest kinnitusid kolm fluoroalkoholi (heksafluoroiso-
propanool – HFIP, heksafluoro-tert-butanool – HFTB ja perfluoropinakool – PP) 
tugevalt C18 statsionaarse faasi pinnale, neist tugevaima interaktsiooniga oli PP. 
Seega võib eeldada, et uuritud eluendilisandid moodustavad anioonse fluoriühen-
dite kihi statsionaarse faasi pinnale, mis on väga ligitõmbav aluselistele po-
laarsetele analüütidele, aga samas eemale tõukav happeliste polaarsete analüü-
tide jaoks. Uuritud lisand nonafluoro-tert-butanool (NFTB) ei kinnitud statsio-
naarse faasi pinnale eriti hästi, samas on ühend madala pKa väärtuse tõttu 
kõrgel eluendi pH-l täielikul deprotoneeritud ja seetõttu omab võimet moo-
dustada mobiilfaasis aluseliste protoneeritud analüütidega ioonpaare. Bifenüül 
ja pentafluorofenüül (PFP) statsionaarsete faaside korral ei kinnitu HFIP ja 
HFTB statsionaarse faasi pinnale ja seega ei moodusta need lisandid fluoro-
alkoholide kihti uuritava statsionaarse faasi pinnale. PP on ainuke eluendilisand, 
mille puhul oli näha piikide pikka ’sabatamist’ (seda ka juhul kui lisandi retent-
siooniaeg statsionaarsel faasil ei olnud pikk) ja seetõttu on võimalik, et see 
lisand moodustab fluoreeritud lisandikihi ka bifenüüli ja PFP statsionaarsete 
faasi pinnale. 
Seega on C18 statsionaarse faasi korral kaks põhilist vastasmõju – (1) ana-
lüüdi vastasmõju fluoroalkoholi kihiga statsionaarsel faasi pinnal ning (2) ana-
lüüdi vastasmõju eluendilisandiga mobiilses faasis. Tavapäraste levinu eluendi-
lisandite (nagu ammoonium atsetaat, ammoonium bikarbonaat ja ammoonium 
formiaat) korral tuleneb muutus retentsioonis vaid muutusest analüüdi polaarse 
[näiteks deprotoneeritud happed (A-) või protoneeriud alused (BH+)] ja mitte-
polaarse [protoneeritud hapete (AH) ja deprotoneeritud aluste (B)] vormi tasa-
kaalus. Seda on eriti hästi näha polaarsete aluseliste analüütide korral, kui ana-
lüütide retentsioon kasvas järsult koos eluendi pH muutusega 8.5-lt 10.0-ni. 
Kuna ioniseeritud ja mitte-ioniseeritud analüüdi vormid ei muutunud pH muu-
tusega, siis kahe neutraalsete analüütide grupi ühendite (AH ja B) retentsioon 
muutus väga vähe. Polaarsete happeliste analüütide jaoks tähendas pH tõus ka 
deprotoneeridud vormi kasvu mobiilfaasis, millega kaasnes analüütide retent-
siooniaja kahanemine mittepolaarsel C18 faasi. 
Muutused analüütide retentsioonis järgivad üldiselt samu mustreid ka uud-
sete eluendi komponentide korral sõltudes peaasjalikult tasakaalust polaarse ja 
mittepolaarse analüüdi vormi vahel. Samas olid uudsete eluendilisandite puhul 
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retentsiooniaja muutused selgemad ning sageli võimendatud. Mittepolaarsete 
analüütide korral varieerusid analüütide retentsioonifaktorid rohkem ja kuna 
enamusel uuritud protoneeritud hapetel on pKa väärtused 10 ligidal ning ana-
lüüdid on seega osaliselt protoneeritud just kõrgel eluendi pH-l. Samal ajal olid 
HFIP ja HFTB kasutamisel nimetatud ühendite retentsioon üldiselt madalam. 
Happelistel anaüütidel olid uudsete eluendilisanditega madalamad retentsiooni-
faktorid võrreldes tavapäraste eluendi komponentidega. See tuleneb sellest, et 
happelised polaarsed analüüdid peavad lisaks statsionaarse faasi nimel konku-
reerimisele ka täiendalat eemale tõukama eluendi koostises olevaid deprotonee-
runud lisandeid HFIP, HFTB, NFTB ja PP. Aluseliste neutraalsete analüütide 
korral täheldati suuremat vaarieeruvust retentsioonifaktorites, ilma selge kasvu 
või vähenemise trendita. Seejuures, uudsete eluendi komponentide vaieldama-
tult suurimat mõju märgati aluseliste polaarsete analüütide puhul. HFIP ja 
HFTB kasutamisel eluendi pH kasvuga kaasnenud tugevam retentsioon oli 
selgemalt näha oluliselt pikemates retentsiooniaegades võrreldes tavapäraste 
eluendilisanditega. Oluline on märkida, et uudsete eluendilisandite kasutamsel 
kasvas valitud analüütide retentsiooniaeg suisa 28 ja 35 korda. Fluoroalkohol 
perfluoropinakool kasutamisel suurenes ühe aluselise protoneeritud analüüdi 
retentsioonifaktor 41 korda. Perfluoropinakool on üks huvitavamaid lisandeid 
kuna omab kahte hüdroksüülrühma, mistõttu perfluoropinakool omab ka kahte 
pKa väärtust. See omakorda tähendab, et perfluoropinakooli on sobilik ioonpaar 
reagent ka madalate mobiilfaasi pH väärtuste juures. NFTB näitas samuti 
eelnevate fluoroalkoholidega sarnast mõju aluseliste analüütide jaoks. 
Oma madala puhverdamisvõime tõttu ei olnud trifluoroetanool (TFE) ja di-
metüülsulfoksiid (DMSO) kasutatavad soovitud kõrgete mobiilfaasi pH-de 8.5 
ja 9.0 juures, ning lisaks nähti ka olulist analüüdi signaali mahasurumist massi-
spektromeetriga analüütide detekteerimisel. Eelnimetatud kahe probleemi tõttu 
ei sobi TFE ja DMSO bioanalüütiliste metoodikate puhul eluendilisanditeks. 
Üldiselt oli analüütide retentsioon bifenüül statsionaarsel faasil tugevam pii-
pii vastasmõjude tõttu, aga on ka erandeid – näiteks analüüdid, mis sisaldavad 
nitro rühma seostusid statsionaarse faasiga väga nõrgalt, isegi juhul kui nende 
struktuuris oli benseenituum, millel omakorda peaks olema tugev interaktsioon 
bifenüül statsionaarse faasiga. Kasutades C18 ja bifenüül statsionaarset faasi 
happeliste analüütide korral esines suurim erinevus retentsioonis eluendi pH-l 
8.5 – kui väiksem osa analüüdist on deprotoneeritud ja täiendava pii-pii või 
halogeen-pii vastasmõju tõttu seostub analüüt tugevamalt bifenüülse statsio-
naarse faasiga. Aluseliste polaarsete analüütide korral, isegi ilma selge pii-pii 
vastasmõjuta (kuna ühelgi protoneeriud aluselisel analüüdil ei ole aromaatset 
tuuma struktuuris) oli retentsioon bifenüül faasil tugevam võrreldes C18 kolon-
niga. Kõrgem logP väärtus tagas ka parema retentsiooni polaarsete aluseliste 
analüütide jaoks. 
Selleks, et rakendada antud uurimustööd praktikasse, uuriti suurt hulka (üle 
100 ühendi) üldlevinud ühendeid (narkootikumid, ravimid), mida kasutatakse 
toksikoloogia sõeluuringutes. Uuritud analüütidel on igal ühel vähemalt üks 
aluseline funktsionaalrühm. Sellise analüütide seguga kasutati difluoroäädik-
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happe (DFA) eluendilisandina ning prooviti ühendeid lahutada C18 statsionaar-
se faasiga. Kui tavapärases puhverlahuses (kuhu on lisatud ka ammoonium for-
miaat) vahetati metaanhape DFA vastu, ei muutunud ainete retentsioon ega 
ionisatsiooni oluliselt. Samas vähenes retentsioon oluliselt 42 analüüdi jaoks 
91-st kui eluendilisandina kasutati DFAd ilma ammoonium formiaadina, antud 
efekt oli tingitud peamiselt eluendi pH langusest. DFA kasutamisel kasvas 
retentsioon analüütidel, mille struktuuris oli happeline funktsionaalrühm. Ana-
lüütide ionisatsiooni uurimisel täheldati, et DFA andis järjepidevalt madalamat 
signaali võrreldes metaanhappe kasutamisega. 
Bifenüülse statsionaarse faasi korral aga vähenes detekteerivate analüütide 
hulk. Pooli analüütidest ei mõjutanud eluendi komponendi vahetamine (ammoo-
nium atsetaadi vahetamine HFTB vastu) ega pH muutus 8.5-lt 9.0-le. HFTB 
kasutamisel eluendi koostises vähenes retentsioon analüütidel, millel on kas 
madal pKa väärtus või mis sisaldavad karboksüülrühma. Analüütidel, mille 
retentsioon kasvas HFTB kasutamisel eluendi koostises, oli kõrgem pKa ja ka 
kõrgem logP väärtus, mis tähendab, et suurem osa analüüdist oli mobiilfaasis 
polaarses vormis ja seega rohkem ligi tõmmatud HFTB poolt. Kui HFTB kasu-
tati eluendi komponendina, siis enamus analüütide signaal kasvas võrreldes am-
moonium atsetaadi kasutamisega, eriti suur kasv oli närgatav eluendi pH 9.0 
juures. 
Suurim erinevus retentsioonis esines PFP kolonni kasutamisel, kuna vaid 42 
analüüdi piigid olid detekteeritavad ja seda ka esialgse happelise mobiilfaasi 
kasutamisel. Analüütidel, mille pKa väärtus on alla 7.6, ei muutunud retent-
sioon oluliselt HFTB kasutamisel eluendilisandina. Taaskord, HFTB kasutami-
sel omavad nõrgemat retentsiooni analüüdid, millel on struktuuris karboksüül-
rühmad. Just nagu varasemalt bifenüül kolonniga, happeliste funktsionaal-
rühmadega analüüdid, mis on deprotoneeritud kõrge pH juures, omavad tugevat 
tõukumist deprotoneeritud uudsete fluorineeritud eluendilisanditega ning tuge-
vat tõmbumist protoneeritud aluselise analüütidega. 
Töös esitleti kahte praktilist rakendust – arendati välja ja valideeriti analüüsi-
metoodikad, et määra ravimite kontsentratsioone vereplasmast farmakokineeti-
liste uuringute jaoks. Mõlemad metoodikad valideeriti täielikul järgides Euroo-
pa Ravimiameti bioanalüütiliste määramismetoodikate valideerimise juhend-
materjali ja saavutades äärmiselt madalad määramispiirid. Lisaks sellele olid 
kasutusel ka äärmiselt väikesed proovikogused. Üks metoodika loodi kolme 
uinutina kasutatava ravimi (morfiini, klonidiini ja midasolaami ning nende 
metaboliite) kvantifitseerimiseks. HFIP-i kasutamine eluendi komponendina 
võimaldas kromatograafiliselt eraldada morfiini ja morfiini metaboliite. Teine 
määramismetoodika, mis keskendus südame ja veresoonkonna haiguste ravimi-
tele milrinoon ja dobutamiin, näitas NH4F kasutamine võimaldab kasvatada olu-
liselt massispektromeetris detekteeritud signaali tugevust (kaks korda milri-
nooni ja seitse korda dobutamiini puhul). Nähtud signaali kasv võimaldas 
saavutada madalamaid määramispiire metoodikale. Täiendavalt viidi läbi ka 
uurimus NH4F mõjust analüüdi ionisatsioonile positiivses detekteerimisrežiimis. 
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Alla määramispiiri jäävaid kontsentratsioone määramismetoodikates ei oli 
rahvusvaheliste juhendmaterjalide alusel lubatud laborist väljastada, kuna nende 
usaldusväärsus on kaheldav. Töös pakuti ka lahendus selliste määramispiiri-
aluste tulemuste hindamiseks kui uudsed eluendilisandid ei pruugi lahendusi 
pakkuda.  
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